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Developing and using methyl-specific antibodies to study
the biological roles of arginine methylation
Vidyasiri Vemulapalli, Ph.D.
Supervisory Professor: Mark T. Bedford, Ph.D.

Arginine residues can be modified in three different ways to produce asymmetric
dimethylarginine (ADMA), symmetric dimethylarginine (SDMA), and monomethylarginine
(MMA). These modifications are catalyzed by a family of nine protein arginine
methyltransferases (PRMT1-9), which are of three types (I, II, and III). The majority of Type I
enzymes asymmetrically dimethylate Glycine- and Arginine-rich (GAR) motifs, except for
PRMT4, which methylates Proline-, Glycine-, and Methionine-rich (PGM) motifs. The same
substrates (GAR or PGM motifs) can also be dimethylated by PRMT5 in a symmetric fashion.
However, it is not clear whether there are dedicated residues within these motifs for ADMA
and SDMA, or if the two enzyme types (I and II) compete for the same arginine residue. In
addition, very little is known about MMA, which commonly occurs as an intermediate in the
pathway to ADMA and SDMA generation. But, occasionally some substrates are solely
monomethylated due to the Type III activity of PRMT7. This project aimed at clarifying the
dynamics of different methylation types using methylarginine-specific antibodies and PRMT
null cell lines. By performing methyl-specific antibody Western and amino acid analysis, we
were able to show that loss of PRMT1, which removes 90% of ADMA, causes a global rise in
MMA and SDMA levels. Hence, we concluded that there is a dynamic interplay among the
three types of methylation, and that ADMA acts as a dominant mark preventing the occurrence
of MMA and SDMA on the same substrates.
The second project also involved methyl-specific antibodies, however, it was aimed at
discovering novel PRMT4 substrates. PRMT4, also referred as coactivator-associated
arginine methyltransferase (CARM1), functions as a regulator of transcription and splicing by
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methylating a diverse array of substrates. In order to broaden our understanding of CARM1’s
mechanistic actions, we generated CARM1 substrate motif antibodies, and used
immunoprecipitation coupled with mass spectrometry to identify novel cellular targets for
CARM1, including Mediator Complex Subunit 12 (MED12) and the lysine methyltransferase
KMT2D/MLL2. Both of these proteins are implicated in enhancer function. We identified the
primary CARM1-mediated MED12 methylation site as arginine 1899. Using methyl-specific
antibodies to this site, we found that MED12 methylation positively correlates with CARM1
levels. ChIP-seq studies reveal that CARM1 and its activity are tightly associated with ERαspecific enhancers and positively modulate transcription of estrogen (E2)-regulated genes.
Using a cell-free biotinylated DNA pulldown assay, we demonstrated that CARM1 and MED12
are co-recruited to a GREB1 estrogen response element (ERE), and in cells, methylated
MED12 efficiently assembles on a multicopy engineered ERE array in response to E2
treatment. Additionally, we show that MED12 interacts with the Tudor domain-containing
effector molecule, TDRD3, in a CARM1-dependent fashion. These findings reveal an arginine
methylation regulatory node on the Mediator complex that may facilitate the communication
between DNA-bound transcription factors and RNA polymerase II.
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Chapter 1: Introduction

1.1 Protein arginine methylation
Proteins acquire functional diversity from a limited repertoire of polypeptides by
undergoing post-translational modifications (PTMs). These modifications regulate the stability,
activity, localization, and binding ability of proteins with its interactors (Deribe et al, 2010).
Protein arginine methylation is a post-translational modification that modulates important
cellular functions like transcription, splicing, signal transduction, and DNA repair (Bedford &
Clarke, 2009). It is catalyzed by a family of enzymes called protein arginine
methyltransferases (PRMTs), which methylate about 0.5% of total arginine residues in
mammalian cells, making it a prevalent modification (Dhar et al, 2013). PRMTs transfer methyl
group(s) (CH3-) from S-adenosyl-L-methionine (SAM) to the terminal nitrogen(s) of the
guanidino group of an arginine residue, giving rise to a methylated protein and the byproduct,
S-adenosyl-L-homocysteine (SAH) (Bedford & Clarke, 2009). Methylation of an arginine
residue does not affect its positive charge, but it changes its shape, increases bulkiness and
hydrophobicity, which in turn affects its protein-protein interactions, both positively and
negatively. For example, methylation of histone H3 tail promotes its interaction with the Tudor
domain of TDRD3 (Yang et al, 2010), whereas methylation of the Sam68 proline-rich motifs
inhibits its interaction with the SH3 domain of p59fyn and PLCγ-1 (Bedford et al, 2000).

1.1.1 Arginine methylation types and the PRMT family
There are three types of methyl-arginine species in cells (Figure 1). ω-NG,NGasymmetric dimethylarginine (ADMA) is the most prevalent type. Here, two methyl groups
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Figure 1: Types of arginine methylation.
The three types of methyl-arginine species occurring in cells are ω-NG-monomethyl arginine
(MMA),

ω-NG,NG-asymmetric

dimethylarginine

(ADMA),

and

ω-NG,N’G-symmetric

dimethylarginine (SDMA).
Figure 1 is adapted from Yang Y, Bedford MT (2013) Protein arginine methyltransferases and
cancer. Nat Rev Cancer 13: 37-50.
Permission has been acquired from the journal to use this figure.
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3

Figure 2: The protein arginine methyltransferase family
The mammalian genome contains nine PRMT genes. All enzymes harbor five signature motifs
(indicated by dark blue vertical lines, a-e. ‘a’ stands for Motif I: VLD/EVGXGXG; ‘b’ stands for
Post I: V/IXG/AXD/E; ‘c’ stands for Motif II: F/I/VDI/L/K; ‘d’ stands for Motif III: LR/KXXG; ‘e’
stands for THW loop. The red vertical lines b, d, and e in PRMT9 are motifs with poor
sequence similarity with the indicated PRMT motifs. TPR stands for tetratricopeptide repeats.
The fourth member of the PRMT family, PRMT4, is otherwise called as co-activator associated
arginine methyltransferase (CARM1).
Figure 2 is adapted from Yang Y, Bedford MT (2013) Protein arginine methyltransferases and
cancer. Nat Rev Cancer 13: 37-50.
Permission has been acquired from the journal to use this figure.
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are added to one of the terminal nitrogen atoms of the guanidium group. The other two types
occur less commonly in cells. They are ω-NG,N’G-symmetric dimethylarginine (SDMA), where
two methyl groups are added to each of the terminal nitrogen atoms of the guanidine group,
and ω-NG-monomethyl arginine (MMA), which has a single methyl group on one of the
terminal nitrogen atoms. The mammalian genome encodes a family of nine PRMT enzymes
(Figure 2), which can be classified into three types: Type I enzymes (PRMT1, 2, 3, 4, 6 and
8) generate ADMA, Type II enzymes (PRMT5 and 9) generate SDMA and the Type III
(PRMT7) enzyme forms MMA residues in mammalian cells. All PRMTs harbor five signature
motifs that are responsible for their methyltransferase activity, and a few additional features
to facilitate their unique functions. For example, protein domains like SH3, Zn finger, prolinerich motif and TPRs, in PRMT2, 3, 8 and 9 enzymes, respectively, aid in substrate recognition;
the myristoyl group at the N-terminus of PRMT8 regulates its subcellular localization.
All PRMTs are ubiquitously expressed, except for PRMT8, which is only expressed in
brain (Lee et al, 2005a). However, they also undergo alternative splicing to produce tissuespecific isoforms. Knockout mice were generated for PRMT1-8 and they show dramatic and
lethal phenotypes, indicating their essential roles in the organism’s development and survival.
Prmt1- and Prmt5-knockout mice die very early during development; Carm1-knockout mice
die at birth and show differentiation defects among many cell types, whereas Prmt2-, Prmt3-,
Prmt6-, Prmt7- and Prmt8-knockout mice are viable with a few abnormalities (refer to Table
1). Additionally, all knockout mice display hypomethylation of their respective substrates,
indicating the non-redundant nature of these PRMTs (Yang & Bedford, 2013).
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Prmt

Knockout mouse phenotype

References

Prmt1

Embryonic lethal by E6.5. Required for
post-implantation development.

(Pawlak et al, 2000; Yu et
al, 2009)

Prmt2

Viable. Null MEFs have increased NF-κB
activity and are more resistant to
apoptosis.

(Yoshimoto et al, 2006)

Prmt3

Viable. Embryos are smaller, but attain
normal size in adulthood.

(Swiercz et al, 2007)

Carm1

Perinatal lethality. Embryos are smaller
and have differentiation defects in T-cells,
adipocytes, chondrocytes, muscle and
lungs. The enzyme-dead knock-in
phenocopies the null.

(Dacwag et al, 2009; Ito et
al, 2009; Kawabe et al,
2012; Kim et al, 2004;
O'Brien et al, 2010; Yadav
et al, 2008; Yadav et al,
2003)

Prmt5

Embryonic lethal by E6.5. Required for
embryonic epiblast cell differentiation.

(Tee et al, 2010)

Prmt6

Viable. Primary knockout MEFs undergo
rapid senescence.

(Neault et al, 2012)

Prmt7

B cell-specific knockout mice are viable
and fertile. Impaired splenic B-cell
development and decreased IgG1 and IgA
production.

(Ying et al, 2015)

Prmt8

Viable. Abnormal motor behaviors such as
hindlimb clasping and hyperactivity.
Altered cerebellar structure and stunted
growth of Purkinje cell dendrites.

(Kim et al, 2015)

Table 1: List of phenotypes for mice lacking prmt1-8 genes.
Adapted and modified from Yang Y, Bedford MT (2013) Protein arginine methyltransferases
and cancer. Nat Rev Cancer 13: 37-50.
Permission has been acquired from the journal to use this figure.
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1.1.2 Regulation of PRMTs
The activity of PRMTs can be regulated through various mechanisms. Certain PTMs
have been shown to regulate PRMT activity. CARM1 undergoes phosphorylation during
mitosis, which prevents dimerization and blocks its enzymatic activity (Feng et al, 2009).
PRMT5 undergoes a pathological phosphorylation, as seen in patients with myeloproliferative
disease, which disrupts its interaction with MEP50 and abolishes its activity (Liu et al, 2011).
PRMT1, CARM1, PRMT6 and PRMT8 are auto-arginine methylated, although the functional
significance of this methylation remains unknown (Dillon et al, 2013; Frankel et al, 2002; Gui
et al, 2011; Kuhn et al, 2011; Sayegh et al, 2007). N-terminal myristoylation was shown to
target PRMT8 to the plasma membrane (Lee et al, 2005a). Secondly, PTMs on histone tails
can block or promote methylation of neighboring arginine residues. For example, histone
H3K18 acetylation by CBP primes the H3 tail for R17 dimethylation by CARM1 (Daujat et al,
2002). H3K9 acetylation blocks H3R8 dimethylation by PRMT5 (Pal et al, 2004). The presence
of H3R8me2a or me2s mark in turn prevents H3K9 methylation by G9a (Rathert et al, 2008).
Another mode of regulation is through protein-protein interactions. Interaction between
PRMT5 and MEP50 is required for the methyltransferase activity of PRMT5 (Friesen et al,
2002). PRMT3 interaction with the tumor suppressor, DAL-1, inhibits its activity (Singh et al,
2004). MicroRNA-mediated expression control is another mode of regulation for PRMTs. For
example, the expression of PRMT5 is inhibited by miR-25, -32, -92, and -92B (Pal et al, 2007;
Wang et al, 2008). In addition, PRMTs also regulate the expression of microRNAs (Mallappa
et al, 2011). Lastly, PRMT activity can be indirectly modulated by the actions of enzymes that
could reverse arginine methylation on proteins. One such enzyme, Jumonji-domain containing
6 (JMJD6), was shown to demethylate H3R2me2 and H4R3me2 marks (Chang et al, 2007;
Gao et al, 2015). However, later studies could not reproduce this work, which makes arginine
demethylation a controversial topic (Webby et al, 2009). If arginine demethylases do exist,
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their discovery would help us better understand and appreciate the dynamic and regulatory
nature of arginine methylation.

1.1.3 Arginine methylation in human disease
The deregulation of PRMTs is observed in many diseases. PRMT1 and CARM1 are
elevated in breast, prostate, and colon cancers (Cheung et al, 2007; El Messaoudi et al, 2006;
Hong et al, 2004; Kim et al, 2010b; Majumder et al, 2006). PRMT1 is also involved in blood
cancers, by interacting with AML1-ETO and promoting its transcriptional activation (Shia et al,
2012). CARM1 functions by methylating the oncogenic protein AIB1, which stabilizes and
enhances its activity (El Messaoudi et al, 2006; Lahusen et al, 2009). PRMT5 is
overexpressed in gastric cancers, lymphomas and leukemias (Kim et al, 2005; Pal et al, 2007;
Wang et al, 2008; Wei et al, 2012). PRMT5 co-operates with SNAIL to downregulate the
expression of E-cadherin, an adhesion molecule lost during the epithelial-mesenchymal
transition (EMT) process in metastatic cancers (Hou et al, 2008). Deregulated arginine
methylation is also implicated in cardiovascular diseases. Nitric oxide (NO) is an important
signaling molecule in cardiovascular, immune, and nervous systems. Nitric oxide synthase
(NOS) catalyzes the generation of NO from L-arginine. The free methylarginine species
(produced by the proteolysis of methylated proteins), MMA and ADMA, but not SDMA, were
shown to inhibit NOS activity (Stuhlinger et al, 2001). The enzyme dimethylarginine
dimethylaminohydrolase

(DDAH)

converts

MMA/ADMA

to

citrulline

and

monomethylamine/dimethylamine, and maintains their intracellular pool size. Deregulation of
PRMT or DDAH enzymes may cause a reduction in NO levels, resulting in endothelial
dysfunction and atherosclerosis. In fact, PRMT1 was shown to be overexpressed in the hearts
of coronary heart disease patients (Chen et al, 2006). The significance of arginine methylation
in viral pathogenesis is evident from the fact that a large number of viral proteins are PRMT
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substrates (E.g. HIV proteins Rev, Tat, nucleocapsid; HSV protein ICP27; HCV protein NS3
and EBNA2) (Boulanger et al, 2005; Kwak et al, 2003). In the HIV cell culture model,
methylation of the viral proteins was shown to increase the virus infectivity (Kwak et al, 2003).
Arginine methylation may function by increasing the interactions between viral and host
proteins, and possibly disrupting host cellular functions.

Section 1.2 serves as the background for Chapter 3
1.2 PRMT1
PRMT1 is the major Type I enzyme, accounting for about 90% of global arginine
methylation in mammalian cells (Tang et al, 2000a). It is involved in a multitude of biological
processes like RNA processing, protein trafficking, signaling, transcriptional activation and
DNA repair (Bedford & Clarke, 2009). These versatile functions of PRMT1 are achieved
through its ability to methylate multiple classes of cellular proteins (Nicholson et al, 2009). The
major class of proteins methylated by PRMT1 is RNA-binding proteins, which include
hnRNPs, fibrillarin, nucleolin, PABPII, Sam68, SLM-1, SLM-2, QKI-5, GRP33, and TAF15
(Bedford & Richard, 2005). Methylation of these proteins seems to be required for their proper
localization and RNA processing ability (Cote et al, 2003). Many signaling pathways are also
influenced by PRMT1-mediated methylation. Insulin treatment of myotubes was shown to
translocate PRMT1 to the plasma membrane, where it methylates several membraneassociated proteins (Iwasaki & Yada, 2007). PRMT1 synergizes with CARM1 and GRIP1 to
enhance Nuclear hormone receptor (NR) -mediated transcription. It methylates the histone
H4 (at Arg3), which further enables H4 acetylation by p300 to enhance transcriptional
activation by NRs (Wang et al, 2001). ERα is also methylated by PRMT1, which is required
for its interaction with PI3K, Src, and FAK (Le Romancer et al, 2008). PPARγ coactivator
(PGC-1α) methylation by PRMT1 induces its target genes (Teyssier et al, 2005). The
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transcription factors, YY1, p53 and NF-κB, associate with and recruit PRMT1 to their target
promoters to methylate the histone H4 tail (at Arg3), suggesting that H4R3me2a is not a
random event and it functions in activating specific gene programs (An et al, 2004; Hassa et
al, 2008; Rezai-Zadeh et al, 2003). PRMT1 also methylates SPT5, which then decreases its
interaction with RNA polymerase II to regulate transcription elongation, in response to viral
and cellular factors (Kwak et al, 2003). The activity of PRMT1 is tightly regulated, which
happens mainly through association with various proteins. The binding of PRMT1 with BTG1,
BTG2, IFNAR1, ILF3 and hCAF1 promotes its methyltransferase activity (Abramovich et al,
1997; Lin et al, 1996; Miyata et al, 2008; Robin-Lespinasse et al, 2007; Tang et al, 2000b),
whereas binding with the orphan nuclear receptor TR3 inhibits its activity (Lei et al, 2009).
Interaction with the pregnane X receptor (PXR) results in nuclear accumulation of PRMT1 (Xie
et al, 2009).
To study the in vivo functions of PRMT1, a Prmt1 null allele was generated in mice,
which resulted in embryonic lethality (at E6.5) (Pawlak et al, 2000; Yu et al, 2009). MEFs
deficient in PRMT1 showed a delay in cell cycle progression, spontaneous DNA damage,
checkpoint defects, aneuploidy, and polyploidy (Yu et al, 2009). The knockout cells also
displayed hypomethylation of PRMT1 substrates including Sam68 and MRE11 (Yu et al,
2009). Hypomethylation of MRE11 impairs its exonuclease activity, but does not affect
complex formation with RAD50 and NBS1 (Boisvert et al, 2005a). Additionally, the recruitment
of HR protein, Rad51, to DNA damage foci is also reduced upon PRMT1 loss (Yu et al, 2009).
Another DNA damage response protein, 53BP1, which promotes NHEJ-mediated repair, is
also methylated by PRMT1 at the GAR motif and this methylation regulates its oligomerization
and interaction with DNA (Boisvert et al, 2005b). These findings underscore the importance
of PRMT1 in genome maintenance and DNA damage response pathway.
The crystal structure of the rat PRMT1 enzyme has been solved and it revealed that
the dimerization of this enzyme is required for AdoMet binding and enzymatic activity (Zhang
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& Cheng, 2003). It also showed that the enzyme has three peptide binding channels, which
may explain how PRMT1 can methylate arginine residues within various sequence contexts
(E.g. RG, RGG, RXR, and other non-GAR motifs) and possess such a wide spectrum of
substrates. Indeed, surface-scanning mutational analysis identified differential enzymatic
activity towards different substrates (E.g. H4 versus GAR) (Lee et al, 2007).
Most of the Type I and Type II PRMTs are known to catalyze substrates in a distributive
manner i.e. they transfer the first methyl group to the substrate and release it before rebinding
to the monomethylated substrate to facilitate the addition of the second methyl group
(Antonysamy et al, 2012; Kolbel et al, 2009; Lakowski & Frankel, 2008; Wang et al, 2014b).
On the contrary, a processive enzyme maintains the interaction with its substrate until both
mono- and dimethylation events occur. However, PRMT1 catalyzes by neither of these
mechanisms. If it works in a fully processive manner, ADMA generation is obligatory i.e. the
concentration of the monomethyl intermediate should not rise above the concentration of the
enzyme. However, the reaction contained equimolar amounts of MMA and ADMA products
even in the presence of excess unmodified substrate (Osborne et al, 2007). If it functions in a
distributive fashion, the monomethyl intermediate should have a much higher affinity for
PRMT1 than an unmodified substrate. Nevertheless, this is not the case (Osborne et al, 2007).
By performing initial velocity, product inhibition and dead-end inhibition studies, Thompson
and Zheng groups confirmed that PRMT1 functions in a partially processive fashion by utilizing
a rapid equilibrium random (RER) mechanism (explained in Figure 3) (Feng et al, 2011;
Obianyo et al, 2008).
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Figure 3: Kinetic mechanism for PRMT1 catalysis.
RER is a type of kinetic mechanism for bisubstrate enzyme reactions where substrates
(denoted by A and B) and products (denoted by P and Q) bind to and dissociate from enzyme
(E) very rapidly. In the first step, PRMT1 (E) binds to AcH4-21 peptide (A) and SAM (B) to
catalyze the first methyl transfer (EAB  EPQ’, P = SAH and Q’ = MMA). In the next step,
either SAH dissociates prior to MMA release, which allows binding of second SAM to the
original E-MMA complex and formation of ADMA product (EAB  EPQ sequentially, Q =
ADMA), or, MMA dissociates prior to SAH release, which then rebinds with a new EB complex
to undergo the second methylation event (EAB  EPQ’, EBQ’  EPQ). This explains the
presence of monomethyl intermediates in the PRMT1 methylation reactions.
Figure 3 is adapted from Obianyo O, Osborne TC, Thompson PR (2008) Kinetic mechanism
of protein arginine methyltransferase 1. Biochemistry 47: 10420-10427
Permission has been acquired from the journal to use this figure.
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Sections 1.3 and 1.4 serve as the background for Chapter 4
1.3 CARM1
CARM1, also known as PRMT4, was first identified in a yeast two-hybrid screen for
GRIP1-binding proteins (Chen et al, 1999). GRIP1/SRC-2 belongs to the p160 family of coactivators (SRC-1, SRC-2, and SRC-3), which facilitate nuclear hormone receptor-mediated
transcription. Upon hormone stimulation, nuclear hormone receptors (NRs) homodimerize,
bind to their cognate hormone response elements (HREs) and recruit p160 co-activators,
which further bring in p300/CBP and pCAF to acetylate histones. Acetylated histones then
recruit SWI/SNF chromatin remodeler complex to increase the accessibility of local chromatin.
NRs also recruit Mediator complex, which communicates with the basal transcription
machinery to facilitate transcription initiation (Stallcup et al, 2003). By using Luciferase
reporter assays, Stallcup group showed that the co-expression of CARM1 along with GRIP1
significantly enhanced HRE-driven reporter gene expression (Figure 4A). They also showed
that mutating CARM1 to disrupt its methyltransferase activity substantially reduced reporter
gene expression (Figure 4A), indicating that CARM1 may function as a secondary co-activator
by methylating its substrates (Chen et al, 1999). Further studies demonstrated that CARM1
methylates p160 coactivators (Feng et al, 2006), the histone acetyltransferases (p300/CBP)
(Daujat et al, 2002; Xu et al, 2001), and the histone H3 (H3R17me2a) (Chen et al, 1999), and
these methylation events influenced NR-mediated transcription positively (Figure 4B). On the
other hand, CARM1 methylation of CBP/p300 disables its interaction with CREB, thereby
preventing CREB-dependent gene activation (Xu et al, 2001). In this context, CARM1
indirectly acts as a transcriptional co-repressor. Aside from this, CARM1 was shown to
coactivate NF-κB, p53, β-catenin and Sox2 transcription factors (An et al, 2004; Covic et al,
2005; Ou et al, 2011; Zhao et al, 2011). Furthermore, ChIP studies using H3R17me2a (a
CARM1 deposited mark) antibody showed elevated
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Figure 4: CARM1 coactivates NR-dependent gene expression
(A) CV-1 cells were transiently transfected with nuclear hormone receptor (NR) (i.e. androgen
receptor (AR), thyroid hormone receptor β1 (TR) or, estrogen receptor (ER)), GRIP1, CARM1,
VLD, and luciferase reporter gene expressing vectors and grown in charcoal-stripped serum
before activating with dihydrotestosterone for AR, triiodothyronine for TR, and estradiol for
ER. Luciferase activities were enhanced 2- to 27-fold by coexpression of GRIP1 with NR, and
further enhanced 2- to 4-fold by coexpression of CARM1 with GRIP1 and NR.
(B) Ligand-activated nuclear receptors, through a p160 scaffold, recruit CARM1, which
partially stimulates transcription by remodeling chromatin (H3R17me2a) in the vicinity of the
gene as well as by modifying non-chromatin substrates (SRC-1, SRC-2, SRC-3 and
p300/CBP). This methylation is interpreted by effector molecules (E.g. TDRD3 ‘reads’
H3R17me2a) that help promote the coactivator function of CARM1.
Figure 4A is adapted from Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad
DW, Stallcup MR (1999) Regulation of transcription by a protein methyltransferase. Science
284: 2174-2177
Permission has been acquired from the journal to use this figure.
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levels at a number of gene promoters including pS2, E2F1, CCNE1, aP2, Oct 4, Sox2,
CITED2, and Scn3b (Bauer et al, 2002; Carascossa et al, 2010; El Messaoudi et al, 2006;
Frietze et al, 2008; Kleinschmidt et al, 2008; O'Brien et al, 2010; Wu et al, 2009; Yadav et al,
2008). Therefore, CARM1 functions as a general transcriptional coactivator.
Gene ablation studies in mice revealed that CARM1 is vital for existence (Yadav et al,
2003). Although the knockout embryos are outwardly developmentally normal (except for their
smaller size), they display a number of cellular differentiation defects such as a partial block
in T-cell development (Kim et al, 2004) and improper differentiation of lung alveolar cells
(O'Brien et al, 2010) and adipocytes (Yadav et al, 2008). Enzyme-dead CARM1 knock-in mice
phenocopy the null mice, indicating that CARM1’s enzymatic activity is required for most of its
in vivo functions (Kim et al, 2010a). Thus a detailed knowledge of the spectrum of proteins
that are methylated by CARM1 is critical for an in-depth understanding of how this enzyme
functions in these different settings.

1.3.1 Identification of CARM1 substrates
Multiple strategies have been used to identify CARM1 substrates including in vitro
substrate screens, candidate approaches, modification-specific antibodies and MS-based
proteomic approaches. The classification of CARM1 substrates based on the functions as well
as screening strategies is shown in Figure 5. The first in vitro screen utilized high-density
protein macroarrays to identify CARM1 substrates. To prepare high-density protein
macroarrays, a human fetal brain cDNA library was cloned into a His-tagged bacterial
expression vector and transformed into E. Coli. The transformants were gridded onto PVDF
filters in a duplicate pattern, grown on agar plates overnight, and induced with IPTG for protein
expression. The filters containing cells were then treated with sodium hydroxide and sodium
chloride solutions, which break open the bacteria and release the protein onto the filter. The
filters (containing 10,000 his-tagged proteins in duplicates) were then incubated
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Figure 5: Classification of CARM1 substrates.
Proteins methylated by CARM1 can be functionally divided into three classes. Transcription
factors (class I) and chromatin regulators (class II) were identified by candidate approaches,
whereas most of the RNA binding substrates (class III) were revealed by macroarray and
small pool screening strategies. In this current study, we aimed at identifying novel substrates
for CARM1 using substrate motif antibodies.
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with recombinant CARM1 and radioactively labeled S-adenosyl-L-methionine ([3H]AdoMet),
washed and exposed to film overnight. This large-scale in situ methylation screen identified
thymocyte cAMP-regulated phosphoprotein (TARPP), polyA binding protein (PABP1), and
CARM1 substrate 3 (CAS3) as CARM1 substrates (Lee & Bedford, 2002). CARM1 knockout
mice undergo a partial developmental block in the early thymocyte progenitors (DN1 to DN2
transition) (Kim et al, 2004; Li et al, 2013). It is speculated that the arginine methylation of
TARPP, whose expression is initiated at the DN2 stage, may contribute to the maturation of
thymocyte progenitors. PABP1 binds the mRNA 3’ polyA tail and the translation initiation factor
to form a closed loop structure that promotes mRNA translation and regulates stability. CAS3
is an uncharacterized protein and is the product of the BC043098 cDNA clone. The functions
of methylation on PABP1 and CAS3 are yet to be identified.
The second approach was a small pool expression screening, modified to identify
CARM1 substrates. Here, a plasmid cDNA library from a mouse B-cell hybridoma (containing
14,000 clones) was generated and divided into pools, each containing ten clones. In vitro
transcription/translation (IVTT) reactions were performed on these plasmid pools using
reticulocyte lysate. Besides the transcription/translation machinery, the lysate also contains
arginine methyltransferases. Hence, addition of radioactively labeled methyl donor, Sadenosyl-L-methionine ([3H]AdoMet) to the IVTT reactions, would label the methyl-accepting
protein products. As expected, the IVTT screen generated labeled proteins, which were
visualized by fluorography. To identify the methylated proteins, the plasmid pools were
deconvoluted and single plasmids were sequenced. This approach identified eleven
methylated proteins, which were further characterized by in vitro methylation reactions using
recombinant PRMTs to determine the specific enzymes responsible for methylating each
substrate. Of the eleven identified substrates, four were CARM1 substrates – snRNP core
protein (SmB), splicing factor 3B subunit 4 (SF3B4/SAP49), U1 snRNP protein (U1C), and
transcription elongation regulator 1 (TCERG1/CA150). The ability of CARM1 to methylate
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several splicing factors and RNA binding proteins underscores its importance in RNA
processing and splicing. In fact, CARM1-mediated methylation of CA150 was shown to
regulate alternative splicing by promoting exon skipping (Cheng et al, 2007).
Most PRMTs (PRMT1, 3, 5, 6 and 8) recognize and methylate a GAR (Glycine and
Arginine-rich) motif (Yang & Bedford, 2013), which has facilitated the development of
methylarginine-specific antibodies that can be used to identify and help characterize
substrates for this class of PRMTs. The first methyl-GAR motif antibodies (ADMA and SDMA)
were developed by Stephane Richard’s group, and used in immunoprecipitation-coupled
mass spectrometry (IP-MS) experiments to identify novel methylated proteins (Boisvert et al,
2003). This approach has recently been expanded upon with the development of additional
antibodies that recognize MMA and ADMA motifs using redundant peptide libraries with fixed
methylarginine residues as antigens (Guo et al, 2014). A screen for CARM1 substrates using
one of these ADMA-specific antibodies identified the chromatin-remodeling factor, BAF155,
as methylated by CARM1. Arginine methylation of BAF155 targets it to genes of the c-myc
pathway, and enhances breast cancer progression and metastasis (Wang et al, 2014a).
An alternative (antibody independent) approach to identifying methylated proteins is
based on a modification of the “stable isotope labeling by amino acids in cell culture” (SILAC)
technique, called heavy methyl SILAC (Ong et al, 2004a). Heavy methyl SILAC exploits the
fact that methionine is taken up by the cell and converted to the sole biological methyl donor,
AdoMet. Thus, if [13CD3]methionine is used in these experiments, heavy methyl groups are
incorporated into in vivo methylated proteins. Using this approach, in combination with
methylarginine enrichment techniques, a large number of PRMT substrates have recently
been identified (Geoghegan et al, 2015; Uhlmann et al, 2012), which comprised the novel
CARM1 substrates found in the current study such as MED12, MLL2 and GPS2.
Other known CARM1 substrates were identified by candidate approaches. HuR and
HuD are RNA-binding proteins that bind AU-rich elements (AREs) of labile mRNAs to stabilize
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them. CARM1 methylates HuD to inhibit its ability to stabilize p21 mRNA, thereby maintaining
the PC12 cells in a proliferative state and preventing neuronal differentiation (Fujiwara et al,
2006). CARM1 methylates HuR and enhances its ability to regulate the turnover of cyclin A,
cyclin B1, c-fos, SIRT1 and p16 mRNAs, thereby regulating replicative senescence (Li et al,
2002; Pang et al, 2013). CARM1 was also shown to regulate muscle differentiation. During
muscle regeneration, satellite stem cells differentiate into Myf5+ satellite myogenic cells and
fuse into myofibers. The expression of Myf5 requires the activation of the transcription factor,
Pax7. CARM1 interacts with and methylates Pax7, which then binds MLL1/MLL2 proteins of
the MLL/ASH2L HMT complex and recruits it to the Myf5 promoter to induce its expression
(Kawabe et al, 2012). CARM1 also methylates the C-terminal domain of RNA polymerase II.
Mutation disrupting this methyl site causes misexpression of snRNAs and snoRNAs,
suggesting that CARM1 methylation of CTD facilitates the transcription of select RNAs (Sims
et al, 2011).
CARM1 has unique substrate specificity, and it does not methylate GAR motifs (Cheng
et al, 2007; Lee & Bedford, 2002). Thus, to facilitate the rapid identification of new CARM1
substrates, we developed CARM1-motif antibody screening strategies to enrich for CARM1methylated proteins. The H3R17me2a antibody (Millipore) was raised against the asymmetric
dimethylarginine 17 mark on histone H3. Immunoblotting protein extracts with this antibody,
however, detected many differentially recognized proteins between wild-type and CARM1
knockout embryos (Cheng et al, 2012; Yadav et al, 2003). These proteins were further
confirmed to be CARM1 substrates (Cheng et al, 2007). Hence, we speculated that CARM1methylated motifs, have a rather loose consensus sequence, and can be used to raise pan
antibodies that would potentially recognize unknown CARM1 substrates. Using a cocktail of
CARM1 methylated motifs as an antigen, we demonstrated that pan CARM1-
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Figure 6: Basic function and modular structure of the Mediator complex.
(A) Mediator is a highly conserved, multi-subunit, coregulator complex required for RNA
polymerase II-dependent transcription. It functions by relaying signals from enhancer-bound
transcription factors to the basal transcription machinery.
(B) The 30 subunits of Mediator exist in four modules: head, middle, tail, and kinase. The
head, middle, and tail modules form the stable core structure, whereas the kinase module is
dissociable from the Mediator complex.
Figure 6 is adapted from Malik S, Roeder RG (2010) The metazoan Mediator co-activator
complex as an integrative hub for transcriptional regulation. Nat Rev Genet 11: 761-772.
Permission has been acquired from the journal to use this figure.
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motif antibodies can be developed. Furthermore, we identified MED12, MLL2, GPS2 and
SLM2 as novel CARM1 substrates, as well as a number of previously characterized CARM1
substrates.

1.4 Mediator Complex
Eukaryotic gene expression is largely dependent on transcription factors (TFs), which
bind to the proximal promoter or the distal enhancer regions of the genes through their DNA
binding domains. Through their activation domains, TFs bind the Mediator complex, which
relays regulatory signals directly to RNA polymerase II (RNAPII) (Figure 6A). Mediator is a
large, multi-subunit complex that is conserved from yeast to humans. In addition to gene
activation, Mediator also regulates chromatin architecture, transcription elongation and
repression. Genetic, biochemical and structural studies have identified that the mammalian
Mediator complex comprises 30 individual subunits that are arranged in four modules – head,
middle, tail and kinase (Figure 6B). Head, middle and tail modules form the stable core
structure, henceforth referred as “core Mediator”. The head and middle modules mainly
associate with the RNAPII machinery, whereas the tail module binds with activator proteins
and regulates various transcriptional programmes (Malik & Roeder, 2010). For example,
MED1 associates with the ligand-inducible nuclear receptors (NRs) such as Thyroid,
Estrogen, Glucocorticoid and PPARɣ receptors (Ge et al, 2008; Ge et al, 2002; Hittelman et
al, 1999; Kang et al, 2002; Malik et al, 2002; Rachez et al, 1999). Studies on Med1-/- cells
highlighted the importance of MED1 in PPARɣ-mediated adipogenesis, GR-mediated
steatosis, TR∝-mediated thermogenesis etc. Similarly, MED23 was shown to interact with
MAPK-regulated factor, ELK1 (Wang et al, 2005). Therefore, Med23-/- MEFs cannot induce
ELK1 target genes (such as Egr2) and consequently fail to undergo insulin-triggered
adipogenesis (Wang et al, 2005). Another tail module subunit, MED15, interacts with SREBP1
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and modulates lipid metabolism (Yang et al, 2006). The kinase module associates in a
reversible manner with the core Mediator to form “CDK-Mediator”. Structural and biochemical
studies suggest that the kinase module binds core Mediator at the same surface, as does
RNAPII, thereby preventing the formation of Mediator-RNAPII holoenzyme (Tsai et al, 2013).
Therefore, the kinase module has been attributed a repressive role in transcription, however,
studies on individual kinase subunits, which include MED13, MED12, CDK8 and Cyclin C,
proved that they function both in transcription activation and repression (Taatjes, 2010). The
dissociation of the kinase module is regulated by the FBW7-mediated proteosomal turnover
of MED13, the subunit that physically links the kinase to the core Mediator (Davis et al, 2013).
Apart from this scaffolding function, MED13 is also involved in developmental gene regulation.
It was shown to repress Wnt- and Notch-target genes in many metazoan model systems
including C. elegans, D. melanogaster and D. rerio (Carrera et al, 2008; Janody & Treisman,
2011). CDK8 functions through multiple mechanisms to regulate transcription, both positively
and negatively. CDK8 phosphorylates TFIIH, which in turn inhibits its kinase activity towards
CTD of RNAPII and represses transcription (Akoulitchev et al, 2000). CDK8 phosphorylates
histone H3 (at Ser 10), which inhibits methylation at H3K9, thereby preventing recruitment of
HP1 to chromatin for epigenetic silencing (Fischle et al, 2005). CDK8 promotes transcription
by enhancing co-activator recruitment. SMAD proteins activated by ligand-induced TGFβ and
BMP receptors are recruited to the target gene enhancers and are phosphorylated by CDK8,
which then recruit YAP protein to facilitate efficient transcription. After transcription, the same
phospho mark on SMAD proteins is recognized by the ubiquitin ligases to facilitate their
degradation (Alarcon et al, 2009). CDK8 positively regulates serum-responsive and hypoxiarelated genes by stimulating RNAPII elongation through recruitment of pTEFb (Donner et al,
2010; Galbraith et al, 2013). Additionally, target genes for p53, Thyroid receptor and phosphoC/EBPβ are positively regulated by CDK8 (Belakavadi & Fondell, 2010; Donner et al, 2007;
Mo et al, 2004). CDK8 also represses genes by phosphorylating and inactivating TFs (E.g.
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E2F1, SREBP1) (Morris et al, 2008; Zhao et al, 2012). It also phosphorylates other TFs (E.g.
Notch ICD, Gcn4, and Msn2) subjecting them to ubiquitin-mediated proteosomal degradation
(Fryer et al, 2004; Rawal et al, 2014).

1.4.1 MED12
The kinase module gene, MED12, is located on X-chromosome (at Xq13) and encodes
a 2212 aa (240kDa sized) protein. This protein can be divided into four distinct domains:
leucine-rich (L) domain, leucine-serine-rich (LS) domain, proline-glutamine-leucine-rich (PQL)
domain and a poly-glutamine (Opa) domain (Figure 7). MED12 is highly conserved among
eukaryotes, particularly in mammals, with 96% identity between mouse and human amino
acid sequences (Philibert & Madan, 2007). Med12 gene is essential for early mouse
development. The null embryos are arrested at the head-fold stage (E7.5), since they cannot
induce mesoderm formation (Rocha et al, 2010). The hypomorphic mutants expressing less
than 10% MED12 protein die at E10.5 and have defects in neural tube closure, axis
elongation, somitogenesis and heart formation. Both canonical Wnt/ -catenin and noncanonical Wnt/PCP pathways are disrupted in these hypomorphic mutants. This is expected
as MED12 physically interacts with β-catenin to activate the transcription of Wnt-responsive
genes (Kim et al, 2006). MED12 was also reported to interact with Nanog and coregulates its
target genes. RNAi-mediated Med12 knockdown was shown to reduce the expression of
Nanog and its target genes in embryonic stem (ES) cells, which then start the differentiation
process (Tutter et al, 2009). In contrast to this, Med12+/+, Med12-/- and Med12hypo ES cells
showed unaltered expression of Nanog and its target genes, suggesting that MED12 is not
required for ES cell pluripotency (Rocha et al, 2010). Nevertheless, MED12 is involved in the
transcriptional regulation of many signaling pathways. Indeed, the C. elegans ortholog of
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Figure 7: Domain structure of MED12.
L  Leucine-rich domain, LS  Leucine- and Serine-rich domain, PQL  Proline-,
Glutamine- and Leucine-rich domain, Opa  Opposite paired domain. FG- (R961W) and
Lujan-related (N1007S) mutations are found in LS domain, the most common uterine
leiomyoma-linked (G44D) mutation is found in the L domain. The methylation site (R1862)
associated with cancer drug sensitivity is present in the PQL domain. The methylation site
(R1899) identified in the current study is also present in the PQL domain. All known interactors
bind MED12 at its PQL domain.
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MED12, dpy-22, was identified to be one of the six highly connected ‘hub’ genes (all of which
encode chromatin regulators) that interact with numerous components of diverse signaling
pathways and serve as modifier genes in multiple mechanistically unrelated genetic diseases
(Lehner et al, 2006). Sox10 is a transcription factor required for terminal differentiation of
myelinating glia. MED12 interacts with Sox10 and induces genes necessary to drive the
myelination of neurons. Glia-specific deletion of Med12 in mice showed defects in terminal
differentiation and myelin gene expression of both Schwann cells and Oligodendrocytes (Vogl
et al, 2013). Amyloid precursor protein (APP), a transmembrane protein associated with
Alzheimer’s disease, is cleaved by γ-secretase to produce amyloid-β (Aβ) peptide and APP
intracellular domain (AICD). Although the events of amyloid-β plaque formation and
consequent neuronal death have been well studied, little is known about the mechanism by
which AICD activates its target genes, which are associated with disease pathology. AICD
was shown to recruit Mediator complex via interaction with MED12 to activate its target genes.
Disruption of this interaction abrogates the transactivation potential of AICD, suggesting that
MED12 plays a crucial role in the pathophysiology of Alzheimer’s disease (Xu et al, 2011). In
addition to this, MED12 is implicated in a number of neurological disorders. Exonic
polymorphisms have been associated with neuropsychiatric diseases including schizophrenia
and psychosis (Philibert, 2006; Sandhu et al, 2003). Recurrent missense mutations in MED12
have been shown to cause X-linked intellectual disability (XLID) syndromes such as OptizKaveggia (or FG) syndrome and Lujan-Fryns (or Lujan) syndrome (Graham & Schwartz, 2013;
Risheg et al, 2007; Schwartz et al, 2007). In addition to mental retardation, these two
syndromes share many overlapping characteristics like macrocephaly, dysgenesis of corpus
callosum, hypotonia, craniofacial dysmorphisms, seizures and behavioural problems. To
understand the molecular mechanisms by which R961W (FG) and N1007S (Lujan) mutations
could contribute to XLID phenotypes, Boyer group identified MED12 binding partners and
studied the biological significance of these interactions. Sonic hedgehog (Shh) acts like a
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morphogen that controls the left-right, dorso-ventral axes patterning, limb patterning and
development of brain, spinal cord and most other organs. The Boyer group showed that Shhactivated Gli3 recruits Mediator complex via interaction with MED12, wherein enzymatically
active CDK8 suppresses Gli3 transactivation activity. R961W and N1007S mutations in
MED12 prevent recruitment of CDK-Mediator to the target gene promoters, thereby
hyperactivating Gli3-dependent Shh signaling that may possibly contribute to XLID
phenotypes (Zhou et al, 2006; Zhou et al, 2012). Repressor element-1 binding factor (REST)
is a transcription factor that represses the expression of neuron-specific genes in terminally
differentiated non-neural tissues or undifferentiated neural precursors. RE1-bound REST
recruits Mediator complex via interactions with MED19 and MED26, wherein MED12 acts as
a direct interface for G9a recruitment and H3K9 dimethylation, leading to epigenetic silencing
of REST-target genes. FG- and Lujan-related MED12 mutations disrupt the epigenetic
restrictions imposed by REST, possibly contributing to XLID phenotypes (Ding et al, 2009;
Ding et al, 2008). Studies by Sheikattar group showed that Mediator interacts with ncRNAactivating (ncRNA-a), a novel class of lncRNAs that activate their neighboring genes using a
cis-mediated mechanism. NcRNA-a3 and -a7 interact with MED12 to recruit Mediator and
deposit CDK8-mediated H3S10 phosphorylation at the promoters of a3 and a7 target genes
(SNAI1, AURKA, and TAL1) for transcriptional activation. They also showed that FG-related
MED12 mutations significantly diminish interactions with ncRNA-a, which may possibly
contribute to XLID (Lai et al, 2013). In addition to neurological disorders, MED12 is also
frequently mutated in human cancers like uterine leiomyomas, breast and prostate cancers
(Schiano et al, 2014). Uterine leiomyoma-linked mutations in MED12 were shown to disrupt
its interaction with Cyclin C-CDK8 resulting in loss of Mediator-associated kinase activity
(Turunen et al, 2014). Furthermore, MED12 is linked to drug resistance in different cancer
types. Cytoplasmic MED12, independent of the Mediator complex, was shown to interact with
the immature form of TGFβR2 and prevent it from undergoing glycosylation and plasma
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membrane association. Therefore, loss of MED12 activates TGFβ signaling that further
causes MEK/ERK activation, which is sufficient to confer multidrug resistance in colon and
lung cancers (Huang et al, 2012). Using genome-scale CRISPR-Cas9 knockout (GeCKO)
library screening, another group identified MED12 as the top hit among genes whose loss
results in drug resistance in melanoma cells (Shalem et al, 2014).
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Chapter 2: Materials and Methods

Contents of this chapter are partially based on Dhar S*, Vemulapalli V*, Patananan AN, Huang
GL, Di Lorenzo A, Richard S, Comb MJ, Guo A, Clarke SG, Bedford MT (2013) Loss of the
major Type I arginine methyltransferase PRMT1 causes substrate scavenging by other
PRMTs. Sci Rep 3: 1311. (* indicates equal contribution authors)
According to Nature Scientific Reports, the author retains the ownership of copyright to
reproduce the contribution or extracts from the original article.

2.1 Antibodies
The details of all the antibodies used in this study are described in tables 2 and 3.

2.2 Plasmids and peptides
The generation of GFP-PRMT1, GFP-PRMT2, GFP-PRMT3, GFP-CARM1, GFPPRMT5, GFP-PRMT6 (Frankel et al., 2002) and GFP-PRMT8 (Lee et al., 2005) constructs
has been described previously. GFP-PRMT7 and GFP-PRMT9 constructs were generated by
cloning the human PRMT7 or PRMT9 cDNA into pEGFP-C1 (Clontech) vector. GST-PABP1
(Lee and Bedford, 2002), GST-CARM1 (Frankel et al., 2002), FLAG-CA150 (Cheng and
Bedford, 2006), GST-Tudor (TDRD3) (Yang and Bedford, 2010), and GST-Tudor (SMN) (Kim
et al., 2006) have been described previously. The other GST-Tudor constructs used in the
pull-down experiments were generated by cloning the Tudor domains of SPF30, SPIN1,
SND1,, and TDRKH, separately, into a pGEX-6p-1 vector (Biomatik). Recombinant H3 protein
used in the in vitro methylation assay was purchased from New England Biolabs. The
p3XFLAG-MED12 plasmid was a gift from Thomas Boyer (University of Texas Health Science
Center at San Antonio). The MLL2a fragment (3619-4285 aa) was amplified from human cDNA
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using gene-specific primers and subcloned into a p3XFLAG-CMV-7.1 vector. FLAG-GPS2
was a gift from Darryl Zeldin (NIEHS). SLM2 plasmid was a gift from Stéphane Richard (McGill
University). FLAG-PABP1 and FLAG-SF3B4 were generated by cloning the cDNAs from
GST-PABP1, and His-SF3B4 (Cheng et al, 2007; Lee & Bedford, 2002). SRC-1, SRC-2, and
SRC-3 constructs were kindly provided by Bert O’Malley (Baylor College of Medicine). FLAGMED12-R1899K and FLAG-MLL2a-R3727K mutants were generated using a QuikChange II
XL Site-Directed Mutagenesis Kit, Agilent Technologies. Biotinylated peptides encompassing
residues 1891-1907 of the MED12 protein with unmodified- or asymmetrically dimethylatedArg1899 were purchased from CPC Scientific.

2.3 Cell lines
The generation of Carm1+/+ and Carm1-/- MEF lines has been described previously
(Yadav et al., 2003). The tamoxifen-inducible Prmt1fl/- ER-Cre MEF line was a gift from
Stephane Richard (McGill University). These MEFs were treated with 2µM 4hydroxytamoxifen, which stabilizes ER*-Cre (A fusion protein between the estrogen receptor
ligand-binding domain and the Cre recombinase) and translocates it to the nucleus, which
then excises the floxed Prmt1 allele to generate PRMT1 knockout MEFs. The generation of
Prmt3+/+ and Prmt3-/- MEF lines has been described previously (Swiercz et al., 2005). Prmt6+/+
and Prmt6-/- MEF lines were created by immortalizing MEFs from PRMT6 WT and KO mice,
according to standard 3T3 protocol. PRMT6 KO mouse was a gift from Stephane Richard
(McGill University). HeLa-shPRMT5 cell lines were a gift from Sharon Dent (UT MD Anderson
Cancer Center). The tetracycline-inducible T-REx-CARM1-293 cell line
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Table 2: Antibodies used in the first study.
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Table 3: Antibodies used in the second study.

32

(Cheng et al, 2007) has been described previously. The MCF-7-Tet-on-shCARM1 cell line
was a gift from Wei Xu (University of Wisconson, Madison). MCF-7, HeLa and HEK293T cell
lines were obtained from ATCC. All cell lines were maintained in Dulbecco modified Eagle
medium containing 10% fetal bovine serum. PRMT1 MEFs were supplemented with 3µg/ml
blasticidin and PRMT5 KD cells were supplemented with 5µg/ml puromycin.

2.4 Amino acid analysis
35–180 mg of wet weight packed MEFs and 100 µL of 6 N HCl were added to a 6 x
50-mm glass tube. Hydrolysis was carried out in a Waters Pico-Tag Vapor-Phase apparatus
in a vacuum vial with an additional 200 µL of 6 N HCl for 18 h at 110°C. After hydrolysates
were vacuum dried, resuspended in 100 µL of water, and centrifuged to remove any debris,
75 µL was added to 250 µL of citrate buffer (0.2 M Na+, pH 2.2) and loaded onto a 0.9 x 8 cm
column of PA-35 sulfonated polystyrene beads (6–12 µm, Benson Polymeric Inc., Sparks,
NV). The column was equilibrated and eluted with citrate buffer (0.35 M Na+, pH 5.27) at 55°C
and a flow rate of 1 mL/min. Individual fractions from 50 to 80 min that included the known
elution positions of ADMA, SDMA, MMA, and arginine were then derivatized with OPA for
fluorescence detection after separation on reverse-phase HPLC.
Amino acids were labeled with OPA by mixing 60 µL of 1 mL cation exchange column
fraction with 20 µL of 0.4 Mpotassium borate (pH 10.3), and 10 µL of OPA reagent (10 mg/mL
OPA powder (Sigma, P0657) in 900 µL methanol, 100 µL 0.4 M potassium borate (pH 10.3),
and 10 µL b-mercaptoethanol). After incubating the mixture at room temperature for 200 s, 5
µL of 0.75 M HCl was added and the sample was vortexed by hand for 5 s. The resulting
fluorescent isoindole derivatives were separated and quantified using reverse-phase HPLC
(HP 1090 II liquid chromatograph coupled to a Gilson Model 121 fluorometer with excitation
and emission filters of 305–395 nm and 430–470 nm, respectively, and a setting of 0.01 RFU).
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An Alltech Adsorbosphere OPA HR (5 mm, 4.6-mm inner diameter, 250-mm length) was used
with 90 µL sample injection volumes at room temperature and a flow rate of 1.5 ml/min.
Solvent A consisted of 50 mM sodium acetate, pH 7.0, and solvent B of 100% methanol. Two
HPLC gradients were used to optimize the quantification of MMA, ADMA, and SDMA (Figure
14). In situations where the fluorometer was overloaded with too much sample, such as in the
case of some fractions associated with the arginine peak, a 1000-fold dilution of the cation
exchange fraction was made in pH 5.27 sodium citrate buffer. Methylated arginine species
were detected based on the HPLC retention time for standards and were confirmed by spiking
the appropriate standard to the sample. Graphpad was used to calculate the area under the
curve for the amino acid of interest. The total amount of a certain amino acid was calculated
by summing every cation exchange fraction’s HPLC run that had the appropriate peak
present.

2.5 Antibody binding assay
CARM1 substrate antibodies were incubated with histone peptide arrays for 90–180
min at 4°C and washed with PBS. Arrays were then probed with the Alexa Fluor 647 labeled
secondary antibody (Invitrogen) for 30–60 min at 4°C, washed with PBS, dried and scanned
using a Typhoon TRIO+ imager (GE Healthcare). Binding intensities were measured using
ImageQuant array software (GE Healthcare).

2.6 In vitro methylation assay
The in vitro methylation reactions contained 1 μg substrate (PABP1, H3 or MED12
peptides), 1 μg recombinant GST-CARM1, 1 μl S-adenosyl-L-[methyl-3H] methionine (81.7
Ci/mmol from a 6.7 μM stock solution, Perkin Elmer, NET155001MC) in a final volume of 30
μl PBS. The reactions were incubated at 30°C for 1.5 h, and boiled in protein loading buffer
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for 5 min. The samples were resolved by SDS-PAGE, transferred onto PVDF membranes,
treated with En3hance (Perkin Elmer, 6NE970C), and exposed to film for 1-3 days at -80°C.

2.7 In vitro phosphorylation assay
The in vitro phosphorylation reactions were performed by incubating 1 μg recombinant
H3 protein, MED12 or CDK8 immunoprecipitated protein A/G beads (from a 10 cm plate), 1
μl non-radiolabelled 10mM ATP in a final volume of 50 μl PBS at 37°C for 1.5 h. The reactions
were stopped by adding protein loading buffer and boiling for 5 min. The samples were
analyzed by Western blotting.

2.8 Peptide pull-down assay
Biotinylated MED12 peptides (20 μg) were immobilized on 20 μl streptavidin agarose
beads (Millipore, 16-126) in 500 μl of mild lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
0.1% Nonidet P-40, 5 mM EDTA, 5 mM EGTA and 15 mM MgCl2) at 4°C for 2 h. The beads
were washed three times with Co-IP buffer and incubated with 4 μg of GST-Tudor protein in
500 μl mild lysis buffer at 4°C for 2 h. After three washes with Co-IP buffer, the beads were
boiled in protein loading buffer and subjected to western blot analysis using αGST antibody.

2.9 Immunoprecipitation and Coimmunoprecipitation assays
For screening CARM1 substrates, HEK293T cells (90% confluent) were transiently
transfected with expression vectors encoding FLAG-tagged putative CARM1 substrates using
Lipofectamine 2000 (Invitrogen). Cells (10 cm plate) were harvested after 24 h, washed with
ice-cold PBS and lysed in 1 ml of RIPA lysis buffer (25 mM Tris-HCl (pH 7.6), 150 mM NaCl,
1% Nonidet P-40, 1% Sodium deoxycholate, 0.1% Sodium dodecyl sulfate, 2 mM EDTA) with
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protease inhibitor cocktail (Roche). The lysates were incubated with 40 μl of anti-FLAG M2
affinity gel (Sigma Aldrich, A2220) for 1 h. The beads were washed three times with RIPA
buffer, eluted in protein loading buffer.
For the co-IP assays, cells (10 cm plate) were transiently transfected with expression
vectors using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
Cells were harvested 30h after transfection and lysed in 1 ml of mild lysis buffer (50 mM TrisHCl, pH 7.5, 150 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 5 mM EGTA and 15 mM MgCl2)
and immunoprecipitated with the specified antibodies.
For the TDRD3-MED12 co-IP experiment, MCF7-tet-on-shCARM1 cells (Yang et al,
2010) were treated with 1 μg/ml of Doxycycline for 6 days to knockdown endogenous CARM1
expression. Untreated parental cells were used as controls. Cells were lysed in buffer A (10
mM HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.05%NP40, pH 7.9) supplemented
with cocktails of protease inhibitor and phosphatase inhibitor (Pierce) for 10 min on ice. After
centrifuging at 4o C at 3000 rpm for 10 min, the supernatant was removed and the pellet was
resuspended in 387 μl of buffer B (5 mM HEPES, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM
DTT, 26% glycerol (v/v), pH7.9) supplemented with 13 μl of 4.6M NaCl to give 150mM NaCl.
After lysing on ice for 10 min, brief sonication was applied to dissolve the pellet. Cell lysates
were kept on ice for additional 30 min. After centrifuge at 24,000 g for 20 min at 4o C, the
supernatant was collected as nuclear extract for immunoprecipitation using anti-TDRD3
antibody.
The immunoprecipitated samples or cell extracts were separated by SDS-PAGE and
transferred onto PVDF membranes. Blots were blocked in PBS-Tween 20 containing 5%
nonfat dry milk and then incubated with the appropriate primary antibody in the blocking buffer
overnight at 4°C. The blots were then washed, probed with an HRP-labeled secondary
antibody and detected using enhanced chemiluminescence (Amersham).

36

2.10 Oligonucleotide pull down assay
A 364 bp doubly biotinylated fragment from the human GREB1 gene was made by
PCR using pCR4-Topo-GREB or pCR4-Topo-GREB ERE mut as a template and purified by
centrifugation through PCR Kleen Spin Columns (Bio-Rad) as detailed in Foulds, C.E. et al.
Mol Cell 2013. Two micrograms of this fragment were bound to 40 μl Dynabeads® M280
streptavidin (Invitrogen) in 150 μl D-PBS as detailed in Foulds, C.E. et al. Mol Cell 2013. MCF7 nuclear extract (NE) was prepared as detailed in Foulds, C.E. et al. Mol Cell 2013. We added
clarified NE (1 mg) to resuspend beads, 100 nM water-soluble E2 (Sigma), and a 1 mM
EDTA/EGTA mix. Reactions were rotated at 4°C for 1.5 hr. Beads were washed two times in
NETN and once in D-PBS as detailed in Foulds, C.E. et al. Mol Cell 2013. After PBS removal,
the final washed endogenous ER-coregulator complexes were resuspended in 20 μl 2x SDS
sample buffer (Pierce) and 9 μl samples were loaded on a 4–15% Mini-PROTEAN® TGX™
Precast gel (Bio-Rad) for immunoblotting using an ECL Plus kit (Pierce) and X-ray film as
detailed in Foulds, C.E. et al. Mol Cell 2013. Sources of primary antibodies were the following:
ERα (sc-543, Santa Cruz Biotechnology), MED12 (A300-774A, Bethyl Laboratories),
meMED12 (Bedford lab rabbit polyclonal), and CARM1 (A300-421A, Bethyl Laboratories).

2.11 Chromatin Immunoprecipitation and quantitative PCR (ChIP-qPCR)
Chromatin was harvested from MCF-7 cells as described previously (Iberg et al, 2008)
and ChIP was performed using CARM1, MED12, and H3R17me2a antibodies. Using 2 μl of
ChIP DNA as the template, qPCR was performed on the ABI 7900 HT Fast Real Time PCR
System (ABI) with primer sets against the specified genes (Table 4). Data was analyzed using
the Sequence Detection System software (ABI). The experimental cycle threshold (Ct) was
calibrated against the input product.
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2.12 ChIP-seq analysis
2.12.1 Mapping of Reads
Sequenced DNA reads were mapped to human genome hg19 using bowtie (version
0.12.8) [1] and only the reads that were mapped to unique position were retained. 31-63
million reads were generated per sample. 80-97% reads were mapped to human genome,
with 59-71% uniquely mapped. To avoid PCR bias, for multiple reads that were mapped to
the same genomic position, only one copy was retained for further analysis. In the final, 2241 million reads were used in peak calling and downstream analyses.

2.12.2 Peak calling and gene annotation
The original peak calling for CARM1/MED12/R17 was done by MACS (version 1.4.2)
[2] using total input DNA as control. The window size was set as 300 bp and the p-value cutoff
was 1e-6. The peaks overlapping DAC Blacklisted Regions and Duke Excluded Regions
downloaded

from

UCSC

genome

browser

(http://genome.ucsc.edu/cgi-

bin/hgFileUi?db=hg19&g=wgEncodeMapability) were removed. Then the peaks from the
three factors were merged (allowing at least 1bp overlap) to form a highly confident superset
of peaks. For each peak from the superset, if it overlapped the peaks of one of the factors
called at p-value 1e-4, it was marked as occupied by the corresponding factor. For ERa, the
peaks were called by MACS with no control used. The window size was set as 300 bp and
the p-value cutoff was 1e-10. The peaks overlapping blacklisted regions were removed. For
public CARM1 data, the peaks were called by MACS by comparing CARM1 E2 treated to both
CARM1 EtOH treated and total input. The window size was set as 300 bp and the p-value
cutoff was 1e-6. Only peaks that were called by comparing to both controls and didn’t overlap
blacklisted regions were kept. For venn diagram of public CARM1 vs. our CARM1, the peaks
(at p-value 1e-6) from both were merged (allowing at least 1bp overlap). For each of the
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merged peaks, if it overlapped the peaks of one of the CARM1 datasets called at p-value 1e4, it was counted as called in the corresponding dataset. Each peak in the superset was
assigned to the gene that has the closest transcription start site (TSS) to it. Then the peak
was classified by its location to the gene: upstream (-50k to -5k from TSS), promoter (-5k to
+0.5k from TSS), exon, intron, TES (-0.5k to +5k from TES) and downstream (+5k to +50k
from TES). The gene list used to annotate the peaks is GENCODE release 19 [3].

2.12.3 Landscape of ChIP-Seq Signal
Each read was extended by 150bp to its 3’ end. The number of reads on each genomic
position was rescaled to normalize the total number of mapped reads to 10M and averaged
over every 10bp window. The normalized values were displayed in UCSC genome browser
(http://genome.ucsc.edu/).

2.12.4 Heatmap and Average Profile of ChIP-Seq Signal around peak center
10kbp upstream and 10kbp downstream from the center of each peak were subdivided
into 250 bp bins. For each ChIP-Seq sample, the rpkm (reads per million reads per kilobase)
values for each bin were calculated and normalized through z-score transformation to
minimize the potential batch effect. The values were then averaged over all peaks to generate
average profile or plotted in heatmap by R function heatmap.2.

2.13 Quantitative Reverse Transcription PCR (RT-qPCR)
MCF-7-Tet-on-shCARM1 cells were untreated or treated with doxycycline (1 μg/ml) for
5 days. The cells were then gently washed with PBS and transferred to phenol red-free DMEM
supplemented with 10% charcoal dextran-stripped FBS. The cells were maintained in this
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media with or without doxycycline for 3 days. On the 9th day, cells were treated with 50nM E2
for 45 min. Total RNA was extracted using RNeasy Mini kit (74104, Qiagen) and cDNA was
synthesized using Superscript III First-Strand Synthesis system (18080-051, Invitrogen).
qPCR was then performed using primer sets against the specified genes (Table 5). Data was
analyzed using the Sequence Detection System software (ABI). The experimental cycle
threshold (Ct) was calibrated against the β-actin control product, and the amount of sample
product from Dox-treated cells relative to that of the control cells was determined using the
DDCt method (1-fold, 100%).

2.14 Immunofluorescence and Image Analysis
Immunofluorescence experiments were performed as previously described (Bolt et al,
2013). Briefly, cells were fixed in 4% formaldehyde in PEM buffer (80 mM potassium PIPES
[pH 6.8], 5 mM EGTA, and 2 mM MgCl2), quenched with 0.1 M ammonium chloride,
permeabilized with 0.5% Triton X-100, non-specific sites were blocked with blotto (5% milk in
Tris-buffered saline/Tween 20), and then specific antibodies were added overnight at 4C prior
to 30 min of secondary antibody (Alexa conjugates; Molecular Probes) and DAPI staining.
Automated imaging was carried out using an IC-200 high throughput microscope (Vala
Sciences). Image fields were acquired with a sCMOS 5.5 megapixel camera through a Nikon
S Fluor 40x/0.90 NA objective. Z-stacks were imaged at 1 µm intervals. Nuclear array
segmentation and signal quantification were performed using PipelinePilot image analysis
software (Biovia) as previously described (Ashcroft et al, 2011; Bolt et al, 2013). Aggregated
cells, mitotic cells, and apoptotic cells were removed using filters based on nuclear size,
nuclear shape, and nuclear intensity.
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Gene Name
GREB1 No peak
GREB1 peak1
GREB1 peak2
GREB1 peak3
GREB1 peak4
FKBP4 No peak
FKBP4 peak
IGFBP4 No peak
IGFBP4 peak
TFF1 No peak
TFF1 peak 1
TFF1 peak 2

Forward Primer
TTTGCATGGACAGGCCTTGA
GAGAGGGTGGTGACACTTGG
CTGGCTGCTTCCTGAGTGG
TGAGCAAAAGCCACAAAGTAGT
GGCTCCAGTCCAAGTACACA
CTTCTCAGTAAGCCTGCGGT
CTCTGCTGTGGAGCCTGC
TTTTGGGTCTGGGTGTGTGT
AGGGTTGGGCAAGGAAAAGT
CCAGGGCCACCGAGAAC
ACATTTGCCTAAGGAGGCCC
ATTTCTTCTCCACGCCCTGT

Table 4: Primers used for ChIP-qPCR assays.
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Reverse Primer
GCCCAAACCTTGGCACTTTC
CTGCAGCTGACAGAGGAGAC
GCGTCAAGCAACTACACTCC
TGCTGCGGCAATCAGAAGTA
AAATGCCACCGTTTCGTGT
GACTATCTGCCGAACCAGGG
TCTCTGATTCTCCCTGGAACCT
CAGCACCTGAGGAGTGCC
CATGCACTTGGGCACTCTGA
CATTCTCGGGGTCAGCACC
ACCTCACCACATGTCGTCTC
GACAGCTGCCAGGTACGG

Gene Name
CARM1
FKBP4
GREB1
IGFBP4
NOB1
TFF1
WWP2
GAPDH

Forward Primer
CCAGGGTGATGATGAAGGAC
CTATCGTGGAGGTTGCACTG
CTGTCCAGAGGGTGACATTG
AGGGGCTGAAGCTGTTGTT
TTGGAAGCAGAGTTTGTTGG
TCCCTCCAGAAGAGGAGTGT
GAAAATTGTCAGCTCTCCGC
AGCCACATCGCTCAGACAC

Table 5: Primers used for RT-qPCR assays.
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Reverse Primer
GGGCATCGCCCTCTACA
CCATAAGGCAGATCCAGGTT
CAGGGATGCTGCTTTAGTGA
CCTGCACACACTGATGCAC
ATGTGCAGAGGTGTTTCTGG
CAGAAGCGTGTCTGAGGTGT
GTCTTGAAGAACAATGGGGG
GCCCAATACGACCAAATCC

Chapter 3: Loss of PRMT1 causes substrate scavenging by other PRMTs

3.1 Mono-methyl arginine antibodies reveal methylation type switching with PRMT1
loss
A panel of five different rabbit monoclonal antibodies (MMA1-5) was generated to
recognize endogenous proteins when monomethylated at arginine residues. MMA1 was
raised against the arginine-glycine-glycine motif, mono-methylated at arginine residue (Rme1G-G) and MMA2-5 antibodies were generated against a synthetic peptide library containing
mono-methyl arginine flanked by degenerate amino acids (XXXXXRme1XXXXX). To validate
these antibodies, we tested them on wild-type and PRMT1-deficient cells. Since PRMT1 is
essential for cell viability, we used an inducible-knockout cell line. The MEF cell line,
heterozygous for the floxed Prmt1 allele, was stably transfected with ER*-Cre (Cre
recombinase fused to the ligand-binding domain of the mouse estrogen receptor (ER)) (Yu et
al, 2009). This Prmt1fl/- ER-Cre MEF line can be treated with 4-hydroxytamoxifen (OHT), which
stabilizes ER*-Cre and translocates it to the nucleus, which then excises the floxed Prmt1
allele to generate PRMT1 KO MEFs. These cells were treated for 8 days with OHT, which is
a few days (2-4 days) prior to cell death, before harvesting cell extracts. PRMT1 has been
known to generate MMA and ADMA marks in vitro. We expected that PRMT1 will mono- and
di-methylate proteins in cells and the loss of this enzyme will lead to the depletion of both
types of methylation. Surprisingly, we found an increase in immunoreactivity with all five MMA
antibodies upon PRMT1 removal (Figure 8A). Additionally, we tested the antibodies on
HCT116 cells untreated or treated with AdOx for 2 days. Adenosine dialdehyde (AdOx) is a
global methylation inhibitor. It functions by inhibiting S-adenosylhomocysteine (SAH)
hydrolase, which leads to the accumulation of intracellular SAH levels. This increase in SAH
levels results in the feedback inhibition for most methyltransferase reactions. Hence, AdOx
treatment should deplete all types of methylation
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Figure 8: Loss of PRMT1 or inhibition of global methylation by AdOx reveals an
accumulation of monomethylated substrates.
(A) PRMT1fl/- ER-Cre MEFs were untreated or treated with 4-hydroxytamoxifen (OHT, 2 μM)
for 8 days. Whole cell lysates were prepared and immunoblotted with αMMA1-5, αADMA, and
αPRMT1 antibodies. Arrow indicates the position of the PRMT1 protein. β-actin serves as a
loading control.
(B) HCT116 cells were treated with AdOx (20 μM) for 48 h and whole cell lysates were
immunoblotted with αMMA1 and a pool of αMMA2-5 antibodies.
Experiment for figure 8B was performed by Cell Signaling Technology.

44

Figure 9: Loss of other Type I enzymes (PRMT3, 4, and 6) or reduction of Type II
enzyme (PRMT5) has no effect on global MMA levels.
Whole cell extracts of wild-type (+/+) and PRMT3 (A), CARM1 (B) or PRMT6 (C) knockout (/-) MEFs were immunoblotted with αMMA1-5, αADMA, and αH3R17me2a (Millipore)
antibodies. (D) HeLa-shControl (C) and HeLa-shPRMT5 (kd1 and kd2) cell extracts were
immunoblotted with αMMA1-5, αSDMA, and αADMA antibodies. All knockout and knockdown
cell lines were validated by immunoblotting with their respective αPRMT antibodies. Arrows
indicate the position of the PRMTs. β-actin serves as a loading control.
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from cellular proteins. However, AdOx-treated cells showed an increased mono-methylation
signal relative to the untreated cells (Figure 8B). Perhaps, AdOx induces MMA accumulation
by partially inhibiting PRMT1 activity. Next, we wanted to determine if this phenomenon holds
true with the removal of other PRMTs. The loss of PRMT3, 4, 6 or the knockdown of PRMT5
did not cause an accumulation of mono-methylated substrates (Figure 9A-D). However, one
protein that migrates at 25 kDa, was mono-methylated upon PRMT5 knockdown (indicated
by solid white arrows in Figure 9D). From these data, we can conclude that the loss of PRMT1
seems unique in its ability to generate mono-methylated substrates. It is also noteworthy that
these antibodies can be used as tools for identifying novel PRMT1 substrates by IP-MS
approaches.

3.2 MMA and SDMA levels reach a maximum within 4-6 days after PRMT1 loss
Next, we wanted to study the dynamics of different types of arginine methylation upon
the gradual loss of PRMT1. This experiment is possible due to the availability of the inducibleknockout PRMT1 cell line (PRMT1fl/- ER-Cre MEFs). These cells were treated with 4hydroxytamoxifen (OHT) and harvested after various time points (0-10 days). Two days post
treatment, 90% of the PRMT1 protein is lost and by 4 days, the cells are completed devoid of
the enzyme (Figure 10D). Concomitant with PRMT1 loss, we observed an increase in MMA
signal (Figure 10A). When tested with ADMA antibody, we observed an initial loss of
methylation among some substrates (Figure 10B – lower molecular weight bands in 2 d and
4 d lanes), which reappeared later (Figure 10B – 6 d to 10 d lanes). We speculated that the
cells could be compensating the loss of PRMT1 by over-expressing other PRMTs. Hence, we
tested the expression of various PRMTs at 4 and 8 days after OHT treatment (Figure 11). At
8-day time-point, we observed an increase in PRMT6 and
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Figure 10: Arginine methylation trends in inducible PRMT1-knockout MEFs.
Prmt1fl/- ER-Cre MEFs were untreated or treated with 4-hydroxytamoxifen (OHT, 2 μM) and
harvested after 0, 2, 4, 6, 7, 8, 9, and 10 days. Whole cell lysates were immunoblotted with
αMMA2 (A), αADMA (B), αSDMA (C) and αPRMT1 (D) antibodies. β-actin serves as a loading
control.
Experiment for figure 10 was performed by Dr. Surbhi Dhar (a previous post-doc from Dr.
Mark Bedford’s lab, UT M.D. Anderson Cancer Center)
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Figure 11: Expression analysis of PRMTs in the absence of PRMT1.
Prmt1fl/- ER-Cre MEFs were untreated or treated with 4-hydroxytamoxifen (OHT, 2 μM) and
harvested after 0, 4, and 8 days. Whole cell extracts were subjected to Western analysis with
αPRMT1, αPRMT3, αCARM1, αPRMT5, αPRMT6, αPRMT7 and αMMA1 antibodies.
Experiment for figure 11 was performed by Dr. Surbhi Dhar (a previous post-doc from Dr.
Mark Bedford’s lab, UT M.D. Anderson Cancer Center)
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PRMT7 expression levels, suggesting that the cells compensated PRMT1 loss by expressing
these 2 enzymes. Additionally, we also noticed streaking of CARM1 by Western analysis,
which could imply hyper protein modification (Figure 11). However, at 4-day time-point, the
cells showed equal expression of PRMT3, 4, 5, 6, and 7 enzymes. This suggests that the
increase in MMA levels upon 4 days of OHT treatment is not due to over-expression of
PRMTs. We also evaluated the dynamics of symmetric di-methylation upon PRMT1 gradual
loss. Like MMA, SDMA levels have also increased with PRMT1 loss (Figure 10C).

3.3 Amino acid analysis confirms the global accumulation of MMA and SDMA levels
with PRMT1 loss
To confirm the above findings using an antibody-independent approach, we performed
amino acid analysis for wild-type and PRMT1 knockout MEFs. To do this, we untreated or
treated Prmt1fl/- ER-Cre MEFs with 4-hydroxytamoxifen (OHT) for 7 days, harvested whole
cell lysates and acid hydrolyzed proteins to obtain amino acids. To quantify methylated
arginine residues, we have developed a novel two-dimensional approach that takes
advantage of the high-resolution of cation-exchange and reverse-phase columns coupled to
the sensitivity of the fluorescent labeling (Figures 12 and 13). PRMT1 wild-type or knockout
acid hydrolysates were first separated by high-resolution cation exchange chromatography.
The fractions obtained were then labeled with o-phthaldialdehyde (OPA) to enable the
detection of picomole levels of amino acids after a second step of separation using two
conditions of reverse-phase HPLC to quantitate MMA, SDMA, and ADMA relative to the level
of arginine (Figure 14). From this study, we were able to measure the changes in different
types of arginine methylation upon PRMT1 loss accurately (Table 2). The loss of PRMT1 has
caused a five-fold increase in MMA levels, a three-fold increase in SDMA levels, and a 50%
reduction in ADMA levels. Consistent with the above antibody studies, amino
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Figure 12: Quantification of MMA, ADMA, SDMA and arginine levels in protein
hydrolysates of wild-type and PRMT1-knockout MEFs.
Cell pellets from wild-type and PRMT1 knockout MEFs were acid hydrolyzed and the resulting
amino acids were separated by high-resolution cation exchange chromatography. (A) Control
chromatograph showing the standards (1 μmol) of ADMA, SDMA and MMA/arginine with
ninhydrin detection. Cell hydrolysates were then chromatographed without standard amino
acids and fractions analyzed by reverse-phase HPLC after derivatization with OPA for
fluorescence quantification as described in "Methods". HPLC conditions were optimized to
separate the large pool of arginine from ADMA and SDMA in wild-type (B) and PRMT1
knockout (C) and from MMA in wild-type (D) and PRMT1 knockout (E) samples. The total
amount of a given species was quantified by summing the integrated area under the curve for
all HPLC fractions containing the respective species that are consistent with the migration on
the cation-exchange column.
Experiment for figure 12 was performed by Grace Huang and Dr. Alexander Patananan from
Dr. Steven Clarke’s lab, UCLA. Wild-type and PRMT1 knockout MEF extracts for the amino
acid analysis were provided by us.
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Figure 13: Workflow for the two-dimensional quantification of MMA, ADMA, SDMA,
and arginine in MEFs.
Figure 13 flowchart was made by Dr. Steven Clarke’s lab, UCLA.
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Figure 14: Reverse-phase HPLC methods optimized to quantify OPA-derivatives of
arginine, MMA, ADMA, and SDMA.
Experiment for figure 14 was performed by Grace Huang and Dr. Alexander Patananan from
Dr. Steven Clarke’s lab, UCLA.
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acid analysis showed that both MMA and SDMA levels rise with the loss of the major protein
arginine methyltransferase. Additionally, these studies also demonstrate the prevalence of
arginine methylation in MEFs. We found that about 0.4% of arginine residues are
asymmetrically di-methylated, 0.01% of arginine residues are mono-methylated, and 0.03%
of arginine residues are symmetrically di-methylated in MEFs (Table 2). Therefore, ADMA is
the predominant mark of methylation in MEFs. We have enlisted here the MMA, ADMA, and
SDMA levels in wild-type MEFs obtained from this study as well as those in rat brain and liver
shown previously in the literature (Table 3). It is noteworthy that while ADMA and SDMA levels
are comparable in MEFs and rat brain and liver, MMA levels are significantly lower in MEFs.

54

Table 6: Average fold change in MMA, ADMA and SDMA levels upon the loss of
PRMT1.
Table 6 was generated by Dr. Steven Clarke’s lab, UCLA.
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Table 7: Comparison of the relative levels of MMA, ADMA, and SDMA in different
mammalian cells.
Values from rat brain and liver were taken from Matsuoka (1972)1 as translated by Paik and
Kim (1980)2, and converted from μ mol per g protein assuming an average arginine residue
content of 5% in proteins.

References for table 7:
1. Matsuoka, M. [Epsilon‐N‐methylated lysine and guanidine‐N‐methylated arginine of
proteins. 3. Presence and distribution in nature and mammals]. Seikagaku 44, 364-70 (1972).
2. Paik, W.K. & Kim, S. Natural occurrence of various methylated amino acid derivatives. (ed.
Meister, A.) (John Wiley & sons, New York, 1980).
Table 7 was generated by Dr. Steven Clarke’s lab, UCLA.
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Chapter 4: CARM1 Methylates Mediator to Promote Estrogen Receptor-Regulated
Transcription

4.1 Developing and characterizing CARM1 Substrate antibodies
Methyl-specific antibodies (both ADMA and SDMA) have previously been used to
identify PRMT substrates (Boisvert et al, 2003; Guo et al, 2014). However, these antibodies
cannot enrich CARM1 substrates because CARM1 does not methylate the glycine and
arginine-rich (GAR) motifs. Indeed, the alignment of methylation motifs of known CARM1
substrates does not create a consensus sequence that could be used for in silico prediction
of additional candidate substrates, although the motif does seem to be proline-rich (Figure
35). Thus, to facilitate the identification of CARM1 substrates, a peptide cocktail of six different
CARM1-methylated motifs (Figure 15A) was used to immunize rabbits to obtain CARM1
substrate antibodies, henceforth referred to as ADMACARM1 antibodies. The four polyclonal
antibodies were affinity purified over a column containing the six peptides.
To characterize ADMACARM1 antibodies, we performed Western analysis on the whole
cell lysates from wild-type (WT) and CARM1 knockout (KO) mouse embryonic fibroblasts
(MEFs) (Figure 15B). ADMA-1CARM1 and ADMA-2CARM1 recognized a slew of bands in the WT
lane, but displayed minimal immunoreactivity in the KO lane. ADMA-3CARM1 showed the loss
of one band, but also a slightly increased signal in the KO lane relative to the WT lane,
suggesting that it might recognize proteins methylated by CARM1 and other Type I PRMTs,
compensating the loss of CARM1 in KO cells. ADMA-4CARM1 seemed to be less
immunoreactive than the other three antibodies, recognizing only a single CARM1 substrate.
As anticipated, the H3R17me2a antibody cross-reacted with a number of proteins in WT cells,
which are absent in CARM1 KO cells. Interestingly, some proteins were recognized in WT
and KO cells at similar levels (indicated by asterisks). Next, we tested the antibodies on
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Figure 15: Characterization of CARM1 substrate antibodies.
(A) The list of peptides used to generate CARM1 Substrate antibodies. (B) Whole cell extracts
from CARM1 wild-type (+/+) and knockout (-/-) MEFs were subjected to western analysis with
αADMACARM1, αH3R17me2a and αCARM1 antibodies. The asterisks on the gels indicate the
positions of the proteins present in both cell lines. Actin blot serves as a loading control. (C)
Prmt1fl/- ER-Cre MEFs were untreated or treated with 4-hydroxytamoxifen (OHT, 2 μM) for 8
days. Whole cell extracts were immunoblotted with αADMACARM1, αH3R17me2a and αPRMT1
antibodies. The solid circles on the gels indicate the positions of the proteins specific to
PRMT1 wild-type (OHT -) MEFs. The arrow points to the position of the PRMT1 protein. Actin
blot serves as a loading control. (D) GST, PABP1 and H3 were methylated in vitro by
recombinant CARM1 in the absence or presence of tritium-labeled AdoMet and subjected to
western analysis with αADMA-2CARM1 antibody (top panel), fluorography (middle panel) and
Coomassie Brilliant Blue staining (bottom panel). GST serves as a negative control.
CARM1 substrate antibodies used in figures 15B-D were generated by Cell Signaling
Technology.
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WT and PRMT1-deficient MEFs. Most proteins were recognized at similar levels in both cell
lines. However, some protein bands were specific to WT cells, not PRMT1-deficient cells
(indicated by solid circles) (Figure 15C). It is noteworthy that these PRMT1-specific proteins
migrated at the same positions as the non-specific proteins observed in CARM1 MEFs
(asterisks in Figure 15B). This suggests that while the ADMACARM1 antibodies primarily
recognize CARM1 substrates, they can also recognize a few PRMT1 substrates. We next
tested the ability of some of the ADMACARM1 antibodies to recognize in vitro methylated
CARM1 substrates. PABP1 and H3 were in vitro methylated by CARM1 in the absence or
presence of tritium-labeled AdoMet. Methylation efficiency was monitored by fluorography
(Figure 15D, middle panel), and duplicate blots were subjected to western blotting using the
ADMACARM1 antibodies. We found that the ADMA-2CARM1 antibody recognized PABP1 and H3
in a methyl-specific fashion (Figure 15D, top panel).
The antibodies were also tested on peptide arrays that harbor a collection of histone
tail modifications, including those deposited by CARM1, PRMT1, PRMT5 and PRMT6. This
peptide microarray currently harbors over 300 modified histone tail peptides. The methylated
arginine motifs include the H3R2, H3R8, H3R17, H3R26 and H4R3 sites. Peptides
representing the mono- and di-methylated forms of these motifs are present on the array. The
dimethyl-H3R17 antibody (Millipore) only recognizes H3R17me2a peptide on the array.
ADMA-2CARM1 behaves very similarly to dimethyl-H3R17 antibody, in terms of site-specific
recognition as well as overall signal intensity. ADMA-3CARM1 also recognizes H3R17me2a, but
weakly (Figure 16). Although ADMA-1CARM1 and ADMA-4CARM1 did not recognize arginine
methylated histone marks, they seemed to be effective in recognizing non-histone substrates
(refer to Figure 17). All antibodies show low leveIs of non-specific recognition, as observed
with H4 unmodified and H3K4me2/T6p peptides (highlighted in red and green,
respectively). These results independently confirm the establishment of a panel of four.
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Figure 16: Histone peptide array analysis of CARM1 substrate antibodies.
The five CARM1 substrate antibodies were tested on peptide arrays that harbor a collection
of over 300 histone tail modifications, including H3R2, H3R8, H3R17, H3R26 and H4R3 (Un, mono- and di-methylated forms) sites. X-axis shows the names of antibodies tested. Y-axis
represents raw binding intensity of the histone peptides with each antibody.
Experiment for figure 16 was performed by Dr. Scott Rothbart, a previous post-doc from Dr.
Brian Strahl’s lab, UNC, Chapel Hill.
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different rabbit polyclonal antibodies that recognize arginine methylated proteins that are
specific to CARM1

4.2 Using ADMACARM1 antibodies to identify CARM1 substrates
A combined immunoprecipitation (IP) and mass spectrometric (MS) approach was
employed to identify CARM1 substrates, using an approach developed for the identification
of tyrosine phosphorylation sites (Rush et al, 2005). Briefly, proteins were extracted from WT
MEFs and digested with trypsin. The resulting complex peptide mixture was partitioned into
three fractions by reversed-phase solid-phase extraction, and each fraction was treated with
one of the four ADMACARM1 antibodies, immobilized on agarose beads. After washing,
peptides were eluted and analyzed by nanoflow LC-MS/MS. The resulting spectra were
assigned to peptide sequences using the program Sequest. Lists of credible methylpeptide
sequence assignments were generated. Using this approach, 112 different proteins were
identified as putative CARM1 substrates. All the identified methylation sites have been
submitted to the PhosphoSitePlus database (www.phosphosite.org). (We sent the WT MEF
extracts to Dr. John Rush at Cell Signaling Technology, who performed the
Immunoprecipitation-Mass Spectrometry experiments on those extracts using CARM1
substrate antibodies.) We selected ten proteins for further evaluation based on the number of
identified methylated peptides in the MS data, and the potential involvement of the candidate
CARM1 substrates in different aspects of chromatin regulation, transcription and RNA
processing (Figure 17A). Out of the ten identified substrates, PABP1 (Lee & Bedford, 2002),
CA150/TCERG1 (Cheng et al, 2007) and SRC-3 (Feng et al, 2006) were described previously
as in vivo CARM1 substrates, thus validating the approach. SF3B4 (Cheng et al, 2007), SRC1 (Feng et al, 2006) and SRC-2 (Feng et al, 2006) were shown to be methylated by CARM1
in vitro. GPS2, KMT2D, SLM2 and MED12 were identified as
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Figure 17: Identification of novel CARM1 substrates.
(A) A table showing the list of CARM1 substrates, identified from the

ADMACARM1 IP-MS

screen, and their functions. The proteins, denoted by an asterisk, were identified as CARM1
substrates for the first time in this study.
(B) The positive hits obtained from the screen were transiently transfected into HEK293T cells
and immunoprecipitated with αFLAG antibody. Western analysis was performed, first with
αFLAG to gauge the expression of the FLAG-tagged proteins (indicated by solid circles), and
then with the αADMACARM1 antibodies. KMT2Da (3619-4285 aa) and SRC-2a (1037-1295 aa)
represent fragments of the full-length KMT2D and SRC-2 proteins.
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potential CARM1 substrates for the first time in this study. GPS2 (G-protein Pathway
Suppressor 2) is an integral component of the NCoR/SMRT/HDAC3 complex (Wong et al,
2014b). The mixed-lineage leukemia 4 methyltransferase (KMT2D) is responsible for
depositing histone H3K4me1/2 marks at enhancers (Ford & Dingwall, 2015; Lee et al, 2013).
SLM2 is a KH domain containing protein that has been implicated in the regulation of
alternative splicing (Traunmuller et al, 2014). To confirm that the identified proteins were
indeed recognized by the methyl-specific antibodies that we developed and used in the
screen, we FLAG-tagged the ten selected proteins, overexpressed them in HEK293T cells,
and then immunoprecipitated them using an anti-FLAG antibody. Western analysis was
performed on the immunoprecipitates, first with an anti-FLAG antibody to confirm the
expression of FLAG-tagged proteins, and then with the ADMACARM1 antibodies (Figure 17B).
Importantly, all ten proteins were recognized by at least one of the four different ADMACARM1
antibodies, and no single antibody recognized all the tagged proteins. These results
demonstrate that none of the four ADMACARM1 antibodies are totally pan CARM1 substrate
antibodies, but they clearly recognize different subsets of CARM1 substrates.
In Figure 15B, we demonstrated that the ADMACARM1 antibodies primarily recognize
CARM1 substrates, but they are also able to engage a few PRMT1 substrates (Figure 15C).
To be sure that the new methylated proteins that we identified are indeed CARM1 and not
PRMT1 substrates, we performed further analysis in CARM1 knockout and knock-down cell
lines that we had previously established (Yadav et al, 2003; Yang et al, 2010). We
immunoprecipitated endogenous MED12 from CARM1 WT and KO MEFs, and then
performed Western blot analysis using ADMACARM1 and H3R17me2a antibodies (Figure 18C).
Both cell lines had the same amount of MED12, but only MED12 isolated from CARM1
expressing cells was immunoreactive with the two methyl-specific antibodies. This indicates
that arginine methylation of MED12 is CARM1-dependent. Additionally, we tested the
antibodies on purified Mediator complex (Figure 18B), and found that they recognize two
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Figure 18: Validation of CARM1 substrates.
(A) Silver stained SDS-PAGE gel analysis of the purified Mediator complex (1 μg). (B)
Western analysis of the purified Mediator complex (1 μg) using αADMA-1CARM1+αADMA3CARM1 antibodies. (C, G, H) Whole cell lysates from CARM1 wild-type (+/+) and knockout (-/) MEFs were immunoprecipitated with antibodies against MED12, SRC-1 or SRC-3 proteins,
and the eluted samples were subjected to western blotting with αADMACARM1 and
αH3R17me2a antibodies. αMED12, αSRC-1, and αSRC-3 blots (bottom panels) demonstrate
equal expression of these proteins in CARM1 wild-type (+/+) and knockout (-/-) MEFs. (D, E
and I) MCF-7-Tet-on-shCARM1 cells were untreated or treated with doxycycline (1 μg/ml) for
8 days and transiently transfected with FLAG-KMT2D, -GPS2 and -SLM2, separately. Total
cell lysates were immunoprecipitated with αFLAG antibody and the eluted samples were
subjected to western blotting with αADMACARM1 and αFLAG antibodies. (F) HeLa cells were
transiently transfected with FLAG control, FLAG-KMT2Da or FLAG-KMT2Da-R3727K. Total
cell lysates were immunoprecipitated with αFLAG antibody and the eluted samples were
subjected to western analysis with αADMACARM1 and αFLAG antibodies. αFLAG blot of the
input samples (bottom panel) shows equal expression of the wild-type and mutant KMT2Da
proteins. KMT2Da represents a fragment (3619-4285 aa) of the full-length KMT2D protein
(NP_003473).
Purified Mediator complex used in figures 18A and 18B was kindly provided by Dr. ChengMing Chiang, UT Southwestern.
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proteins – one that migrates at the same position as MED12 and another at around 90kDa
(which could be MED24 or MED16, presumed based on the silver stained complex (Figure
18A)). This suggests that MED12 may not be the sole target for CARM1 in the Mediator
complex. GPS2, KMT2D and SLM2 were not tested in this assay because we were unable to
find specific antibodies that were able to immunoprecipitate the respective endogenous
proteins. We thus overexpressed FLAG-GPS2 in control and CARM1-knockdown cells, and
then performed Western blotting of the FLAG immunoprecipitates using ADMACARM1
antibodies to show that GPS2 is specifically recognized in control cells, but not in CARM1knockdown cells (Figure 18D). In the case of KMT2D, owing to its large size (5537 aa), we
cloned a fragment (3619-4285 aa) of the full-length KMT2D protein, which harbors the mass
spectrometry identified methylation site (R3727). We also engineered a R3727K mutation at
this site in the FLAG-KMT2Da construct (QuikChange II XL Site-Directed Mutagenesis Kit,
Agilent Technologies), and found that the ADMACARM1 signal is significantly reduced in the
R3727K-MLL2a mutant, relative to the wildtype-MLL2a protein, indicating that R3727 is a major
site for CARM1 methylation (Figures 18E and 18F). Finally, we also confirmed that steroid
receptor coactivators SRC-1 (Figure 18G) and SRC-3 (Figure 18H) are recognized in a
CARM-dependent fashion by the ADMACARM1 antibodies. Interestingly, when SLM2 was tested
in CARM1 knockdown cell lines, we did not observe a loss of methylation (Figure 18I),
although this protein is recognized by a number of CARM1 substrate antibodies. Instead, we
observed an increased signal with ADMA-3CARM1, which indicates overcompensation by
another type I enzyme. Hence, SLM2 may be targeted by more than one PRMT.

4.3 Mediator subunit 12 is methylated at Arginine 1899 by CARM1 in vivo
The mass spectrometry studies identified MED12-R1899 as a major site of CARM1
methylation. To characterize the methylation site in more detail, we raised two independent
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Figure 19: Characterization of the meMED12 antibodies.
(A) Whole cell extracts from CARM1 wild-type (+/+) and knockout (-/-) MEFs were subjected
to western analysis with αmeMED12a, αmeMED12b and αMED12 antibodies. The arrow points
to the position of the MED12 protein. Actin blot serves as a loading control. (B) CARM1 wildtype (+/+) and knockout (-/-) MEFs were immunoprecipitated with αmeMED12a, αmeMED12b
and αMED12 antibodies and the eluted samples were subjected to western blotting with
αMED12 antibody. (C) HEK293T cells were transiently transfected with FLAG, FLAG-MED12
or FLAG-MED12-R1899K (NP_005111). Total cell lysates were immunoprecipitated with
αFLAG antibody and the eluted samples were subjected to western analysis with αmeMED12a
and αFLAG antibodies. (D) T-REx-CARM1-293 cells were treated with tetracycline and
harvested after 0, 4, 12, 24, and 48h. Whole cell extracts were immunoblotted with the
indicated antibodies. β-actin blot serves as a loading control.
Methyl-MED12 antibodies used in figures 19A-D were generated by Cell Signaling
Technology.
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antibodies against a MED12-R1899me2a peptide. Western blot analysis of CARM1 WT and
KO MEF extracts showed that both antibodies detect a 240kDa protein (the size of MED12)
and a few other potential substrates, in a CARM1-dependent manner (Figure 19A).
MeMED12b was more selective and only recognized one additional band of about 200kDa.
To confirm that the 240kDa protein is MED12, we immunoprecipitated methylated MED12
from WT and CARM1 KO MEF lysates with the meMED12 antibodies and blotted with the
MED12 (Bethyl) antibody. We found that both meMED12 antibodies selectively enriched
MED12 protein from WT cells (Figure 19B). To confirm that the meMED12a antibodies are
site-specific, we made a R1899K point mutation (QuikChange II XL Site-Directed Mutagenesis
Kit, Agilent Technologies) in the full-length FLAG-MED12 construct, immunoprecipitated the
wild-type and mutant forms from transiently expressing HEK293T cells and blotted with
meMED12a antibody. The antibody detected the wild-type form of FLAG-MED12 strongly, but
not the mutant form (Figure 19C). All these data clearly show that MED12 is methylated by
CARM1 at R1899.
To further characterize the binding specificity of meMED12 antibodies, we tested them
on the Oriented Peptide Array Library (OPAL). In this oriented KGXXXXRme2aXXXXGKbiotin peptide library, X denotes degenerate position and central-R is asymmetrically
dimethylated (Figure 20A). For example, the position P-4 is fixed (Z) in the
KGZXXXRXXXXGK-biotin library, 19 different libraries will be synthesized, and each library
will have one of the 19 amino acids (excluding cysteine) fixed at position Z. For the next row,
the Z position moves to P-3 (three residues up from the fixed arginine), and again 19 different
libraries are synthesized. A total of 152 (19 amino acids x 8 positions) library pools were
synthesized and printed onto a streptavidin-coated glass slide. When meMED12 antibody is
incubated with this OPAL, we observed strong binding at P+1 and P+2 positions, where
Glutamine (Q) was selected (Figure 20B). Tyrosine (Y) was preferred strongly at P-1 position,
and Phenylalanine (F) weakly. Weaker binding was also observed at P-3 position,
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Figure 20: Binding specificity of methyl-MED12 antibody determined by OPAL.
(A) Degenerate peptide sequence used to synthesize OPAL peptide array library. (B) The
OPAL library, containing 152 peptide (KGXXXXRme2aXXXXGK) pools, is incubated with
αmeMED12(a&b) antibodies and detected using a fluorescently labeled secondary antibody. X
represents random amino acids (except cysteine). (C) Alignment showing high conservation
of MED12 methylation motif (SVYRQQQ) among vertebrates.
Figure 20B – Experiment performed and figure organized by EpiCypher, NC
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where Serine (S) was selected. The motif preferred by the meMED12 antibody (S-X-Y/FRme2a-Q-Q-X) is highly comparable with the MED12 methylation motif (S-V-Y-Rme2a-Q-QQ), hence confirming the antibody’s binding specificity. We also aligned the Human MED12
methylation motif with the MED12 sequences of various vertebrates and found that R1899 is
highly conserved among these species (highlighted in black) (Figure 20C). R1899 flanking
amino acids recognized by the meMED12 antibody (highlighted in grey) were also conserved.
CARM1 occasionally interacts with its substrates (Feng et al, 2006; Kowenz-Leutz et
al, 2010; Wang et al, 2014a). To determine if CARM1 interacts with the Mediator complex, we
performed reciprocal co-immunoprecipitation experiments between CARM1 and Mediator
subunits (MED12, MED4, MED30, and CDK8) from HeLa cells. We found that CARM1 does
not interact with the Mediator complex (Figure 21A). Thus, CARM1 and MED12 are likely
transiently engaged. We also tested if MED12 methylation has a role in Mediator complex
assembly. Co-immunoprecipitations were performed between MED12 and other Mediator
subunits in WT and CARM1 KO MEFs. We found that the MED12 antibody coimmunoprecipitated Mediator subunits (MED4, MED30, and CDK8) from WT and KO cells at
similar levels. This suggests that MED12 is incorporated into the Mediator complex,
irrespective of its methylation status (Figure 21B).
Since MED12 belongs to the CDK8 module, we wanted to determine if R1899
methylation of MED12 affects the kinase activity of CDK8. So, we immunoprecipitated the
CDK8 subcomplex using CDK8 or MED12 antibodies from wild-type versus CARM1 knockout
cells and used as an enzyme source to perform in vitro phosphorylation of recombinant
histone H3. Immunoprecipitates (MED12 or CDK8) from both wild-type and CARM1 knockout
cells phosphorylated the histone H3 (at S10) at similar levels, as observed by the pH3S10
immunoblot (Figure 22). This suggests that MED12 methylation has no effect on CDK8 kinase
activity towards H3.
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Figure 21: CARM1 - Mediator interactions
(A) HeLa whole cell lysates were subjected to immunoprecipitation using IgG or antibodies
specific for MED12, CDK8, MED4, MED30 and CARM1. Western blotting was performed on
the immunoprecipitates using antibodies against CARM1 or the indicated Mediator subunits.
(B) Whole cell extracts from CARM1 wild-type (+/+) and knockout (-/-) MEFs were
immunoprecipitated with αMED12 antibody and subjected to western analysis using
antibodies specific for the indicated mediator subunits.
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Figure 22: MED12 methylation does not affect CDK8 kinase activity.
Recombinant H3 protein is in vitro phosphorylated using MED12 or CDK8 immunoprecipitates
from wild-type (+/+) or CARM1 knockout (-/-) MEFs in the presence of the phosphate donor,
adenosine-5’-triphosphate, and immunoblotted with αpH3S10, αCDK8 and αMED12
antibodies. Ponceau stained blot shows equal loading of H3 protein.
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Arginine methylated proteins, PABP1 and SAP145, are thought to be fully methylated
in cells (Yang et al, 2015; Zeng et al, 2013), suggesting that these are not regulatable signaling
nodes. To test if MED12 is fully methylated in cells, we employed the tetracycline-inducible
CARM1-Flp-In HEK293 cell system (Cheng et al, 2007). Upon the induction of CARM1
expression, we observed an increase in MED12 methylation levels, as detected by the
meMED12a antibody (Figure 19D). On the other hand, methylated PABP1 levels did not
change with CARM1 induction, as expected. Therefore, MED12 is not fully methylated in cells,
and the dynamic changes in methylation levels upon CARM1 expression point toward a
regulatory role for this R1899 methylation. Thus, transient association of CARM1 with MED12
at enhancer elements may induce local methylation of the R1899 site to facilitate the docking
of an effector molecule.

4.4 Methylated MED12 interacts with the effector molecule TDRD3
Effector molecules for both ADMA and SDMA motifs are Tudor-domain containing
proteins (Cote & Richard, 2005; Gayatri & Bedford, 2014). For example, the Tudor domain of
SMN binds spliceosomal proteins like SmB (Brahms et al, 2001; Friesen et al, 2001) and
SAP145 (Yang et al, 2015), and TDRD3 was shown to bind the CARM1 histone code mark,
H3R17me2a (Yang et al, 2010). To determine if MED12 interacts with any of the known
methylarginine “reading” Tudor domain-containing proteins, we synthesized biotin-tagged,
unmodified and methylated, MED12 peptides and validated them by an in vitro methylation
assay. As expected, recombinant CARM1 methylated the unmodified MED12 peptide in vitro
but not the methylated peptide, which has no methyl-acceptor position (Figure 23A). This
experiment also independently confirms that the MED12 R1899 site is a good CARM1
methylation motif. These peptides were then used to pull-down GST-fused Tudor domains

75

Figure 23: MED12 - TDRD3 interactions
(A) Fluorograph (top panel) and Coomassie Brilliant Blue staining (bottom panel) of the
peptides in vitro methylated by recombinant CARM1 in the presence of tritium-labeled
AdoMet. (B) The peptides were used to pull down tudor domains of the indicated proteins.
The input samples and the eluted samples were immunoblotted with αGST antibody.
Streptavidin HRP blot serves as a peptide loading control. (C) MCF-7-Tet-on-shCARM1 cells
were untreated or treated with doxycycline (1 μg/ml) for 8 days. Nuclear extracts were
subjected to immunoprecipitation with αTDRD3 antibody and the eluted samples were
detected by western blotting with αMED12 and αTDRD3. The input samples were
immunoblotted with αTDRD3, αMED12, αmeMED12a and αCARM1.
Figure 23C – Experiment performed and figure organized by Dr. Yanzhong Yang, a previous
post-doc from Bedford lab, UT M.D. Anderson Cancer Center.
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of TDRD3, SMN, SPF30, TDRKH, SPIN1 and SND1, the six best-characterized
methylarginine “reading” Tudor domain-containing proteins (Gayatri & Bedford, 2014). Pulldown experiments demonstrated that the Tudor domains of TDRD3 bound strongly to the
methylated form of the MED12 peptide, and SMN bound weakly (Figure 23B). Next, we
endeavored to confirm that MED12 interacts with TDRD3 in cells, and that this interaction is
CARM1-dependent. To do this, we used CARM-inducible knockdown cells, and
immunoprecipitated TDRD3 from CARM1 WT and KD cells. TDRD3 co-immunoprecipitated
MED12 from WT but not KD cells (Figure 23C). Input controls show that CARM1 was
efficiently knocked-down and that MED12 methylation levels were decreased. These data
establish that TDRD3 interacts with MED12 in a CARM1-dependent manner.
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Figure 24: MED12 methylation status in breast cancer subtypes.
Western analysis was performed on a panel of 14 breast cancer cell lines using (A) αERα,
αmeMED12-1 (also called meMED12a), αMED12, (B) αCARM1 and αPRMT1 antibodies. βactin blots serve as loading controls.
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4.5 Genome-wide analysis of CARM1, MED12 and H3R17me2a in MCF-7 cells
To perform methyl-MED12 ChIP-seq studies, we wanted to choose a cell line with
relatively high levels of MED12 methylation. Hence, we obtained whole cell extracts for a
panel of 14 breast cancer subtypes (obtained from MD Anderson characterized cell line core
facility) and tested for total- and methylated-MED12 levels. We found that MED12 is variably
expressed across different cell lines, and it is highly methylated in the ERα positive MCF-7
cell line (Figure 24A). However, we did not observe any correlation between R1899
methylation levels and CARM1 expression levels or the hormone receptor status (Figure 24B).
In order to determine the chromatin distribution of methylated MED12 in MCF-7 cells,
we developed two methyl-specific MED12 antibodies (meMED12a&b). In addition to methylated
MED12, the antibodies recognized at least one other CARM1 substrate (Figure 19A). Owing
to their non-specific nature, ChIP-seq experiments for the methylated form of MED12 could
not be attempted with these antibodies. Hence, to indirectly define methylated MED12
chromatin associated regions, we performed ChIP-seq analysis using MED12 (total), CARM1,
and H3R17me2a antibodies. The H3R17me2a antibody (Millipore) recognizes a number of
different CARM1 substrates, including MED12 (Figure 18C), SRC-3 (Figure 18H), CA150
(Cheng et al, 2007), and SmB (Cheng et al, 2007). The H3R17me2a antibody is not totally
pan, because it does not recognize the methyl-motifs on KMT2D and SRC2 (Figure 17B).
Therefore, ChIP-seq with this antibody provides a genomic readout for most CARM1 activity,
not just for the histone mark alone. From the ChIP-seq data, we detected 992 MED12 binding
sites, 743 CARM1 binding sites, and 726 peaks enriched for CARM1 activity in proliferating
MCF-7 cells, grown in phenol red-containing media. We observed a 33% (410 out of total
1234 binding sites) overlap of the CARM1, MED12, and CARM1 activity profiles (Figure 25A).
Analysis of the overlapping peaks identified a number of estrogen-regulated genes. We then
compared our ChIP-seq data with the binding profiles
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Figure 25: ChIP-seq analysis of CARM1, MED12, and H3R17me2a in MCF-7 cells.
(A) Venn diagram showing an overlap between CARM1-, MED12- and H3R17me2a-binding
sites on the MCF-7 genome. (B & C) Heatmap and distribution figures depict profiles for
genome-wide localization of CARM1, MED12, H3R17me2a, ERα, enhancer (H3K4me1 &
H3K27ac), promoter (H3K4me3) and repressor (H3K27me3) marks. Categories: YYY – peaks
co-occupied by CARM1, MED12 and H3R17me2a, YYN – peaks co-occupied by CARM1 and
MED12, YNY – peaks co-occupied by CARM1 and H3R17me2a, NYY – peaks co-occupied
by MED12 and H3R17me2a, YNN, NYN and NNY – peaks occupied by CARM1, MED12, and
H3R17me2a, respectively. (D) Comparison of the binding motifs for MED12, CARM1,
H3R17me2a, and ERα. Motif analysis was done using MEME suite.
Figure 25A-D – ChIP-seq experiments were performed by Dr. Donghang Cheng from The
University of Texas MD Anderson Cancer Center. ChIP-seq data analysis was performed by
Dr. Yue Lu from The University of Texas MD Anderson Cancer Center.
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Figure 26: Overlap between ER peaks and promoter peaks
(A) Percentage of peaks overlapping ERα binding sites and percentage of peaks in promoter;
ER∝ peaks were called by MACS at p-value 1e-10. Promoter was defined as -5000bp to
+500bp from transcription start site (TSS).
(B) Comparison between the binding motifs of SP1 and YYN+YNN peaks.
Figure 26 was generated by Dr. Yue Lu from The University of Texas MD Anderson Cancer
Center.
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of ERα and various histone modifications associated with enhancer (H3K4me1 and
H3K27ac), promoter (H3K4me3) and repressed (H3K27me3) regions (Figure 25B). ChIP-seq
peaks from all these experiments correlate highly with functional enhancers, moderately with
active promoters, but show no overlap with the repressed regions. In addition, our ChIP-seq
data also displayed good overlap between H3R17me2a, active enhancer marks and the
enhancer-bound protein, MED12, which confirms the ChIP-on-chip studies performed by the
Miles Brown group that reported CARM1 activity predominantly at enhancer regions in MCF7 cells (Lupien et al, 2009). Importantly, 60% of the peaks co-occupied by CARM1, MED12
and H3R17me2a (Category YYY) overlap with ERα peaks, indicating that these Mediatorbound regions targeted by CARM1 are ERα-specific enhancers. The H3K27ac and H3K4me1
marks decorate the edges of active enhancers, creating a trough where the TFs and
coregulators are enriched. It is in this trough that we see CARM1, MED12, CARM1 activity
and ERα signals (Figure 25C). In addition, motif analysis of CARM1, MED12 and CARM1
activity peaks revealed a consensus sequence that is almost identical to the ERα-binding motif
(Figure 25D). It is noteworthy that a subset of peaks, which are weak in ERα and H3R17me2a
signal, associated with active promoters (i.e. Categories YYN and YNN overlap well with
H3K4me3 signal) (Figure 25B & 26A). We speculate that these peaks may constitute a distinct
class of CARM1-regulated genes that do not associate with ERα. Indeed, Motif analysis under
this subset of H3K4me3 peaks identified a binding motif for SP1 (Figure 26B), suggesting that
this basal transcription factor may also make use of CARM1’s coactivator activity.
To highlight the degree of co-occupancy of CARM1, MED12, and CARM1 activity at
EREs, we focused on the well-characterized ERα target, GREB1, which has four well-defined
EREs (Carroll et al, 2006) (Figure 27A). Similar tight overlap of these three ChIP-seq profiles
are also seen at the TFF1, IGFBP4, and FKBP4 loci (Figures 28A-C). The peak
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Figure 27: Regulation of ChIP-seq target genes by MED12 methylation.
(A) ChIP-seq peaks demonstrating the enrichment of MED12, CARM1, and H3R17me2a
signals at the GREB1 gene locus. (B) ChIP-qPCR analysis of the association of MED12,
CARM1, and H3R17me2a with GREB1 gene. (C) MCF-7-Tet-on-shCARM1 cells were
untreated or treated with doxycycline (1 μg/ml) for 8 days. Total RNA was extracted and RTPCR was performed using primers specific for the genes shown. GAPDH acts as a negative
control. Target gene expression was normalized to Actin. Error bars represent standard
deviation based on three independent experiments. * (p<0.05), ** (p<0.01) and *** (p<0.001).
Figure 27 – Experiments were performed by Dr. Donghang Cheng from The University of
Texas MD Anderson Cancer Center.
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Figure 28: Confirmation of ChIP-seq peaks for the target genes.
ChIP-seq peaks and qPCR analysis demonstrating the enrichment of MED12, CARM1, and
H3R17me2a signals at TFF1 (A), IGFBP4 (B), and FKBP4 (C) gene loci in MCF-7 cells.
Figure 27 – Experiments were performed by Dr. Donghang Cheng from The University of
Texas MD Anderson Cancer Center.
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Figure 29: MED12 methylation levels do not correlate with ER levels.
MCF-7 cells were untreated or treated with Fulvestrant (100 nM) for 4 h. Whole cell,
cytoplasmic and nuclear extracts were harvested and immunoblotted with αmeMED12a,
αMED12, αERα antibodies. LDH, Lamin A/C, and β-actin blots serve as loading controls.
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correlation between CARM1, MED12 and H3R17me2a was confirmed by ChIP-qPCR (Figure
27B & 28). Next, six target genes that displayed strong overlap of all three ChIP-seq profiles
(GREB1, TFF1, IGFBP4, FKBP4, NOB1 and WWP2), were tested for their dependency on
CARM1 for optimal E2-induced expression. To do this, a Tet-inducible CARM1 shRNAknockdown cell line was used. CARM1 knockdown significantly reduced the expression of all
six tested genes (Figure 27C). Since MED12 occupancy and CARM1 activity is prominent at
EREs, we speculated that MED12 methylation may be triggered through the ERα pathway.
To address this question, we treated MCF-7 breast cancer cells with an ERα antagonist,
Fulvestrant. With the reduction of ERα levels, we found that MED12 methylation remained
stable (Figure 29), indicating that this methylation event is not downstream of the ERα
pathway.

4.6 The dynamics of CARM1 and MED12 recruitment to EREs
It is well established that ERα orchestrates the ordered and cyclical assembly of
transcriptional coactivators and chromatin remodelers at EREs (Metivier et al, 2003). The first
cycle of transcription, which is established within 15 minutes of E2-treatment, involves the
recruitment of PRMT1, but not CARM1. Mediator is not part of this first round either.
Subsequent cycles of transcription initiation that have an interval of about 40 minutes recruit
CARM1 preferentially over PRMT1. To gain an understanding of the dynamics of CARM1 and
MED12 subcellular localization after MCF7 cells were treated with estrogen, we investigated
the timing of nuclear accumulation of these factors, and potential alterations in the modified
state of MED12. ERα rapidly translocates into the nucleus in response to E2 (Figure 30A), as
expected. Interestingly, and previously unreported, the pool of nuclear CARM1 increases after
1 hour of E2-treatment, perhaps to support the “productive” cycles of transcription, which
seem to favor the use of CARM1 over PRMT1 (Metivier et al, 2003). Nuclear MED12 levels
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do not fluctuate after E2-treatment, and no dramatic increase in nuclear MED12 methylation
is observed during this time course (Figure 30A). Next, we asked if methylated MED12 was
recruited to EREs. Again, using the four GREB-linked EREs we find that methylated MED12
recruitment peaks at 1-hour after E2-treatment (Figure 30B), which is the same timing as
Mediator recruitment (Metivier et al, 2003). The same holds true for TFF1, TGFBP4, and
FKBP4 (Figure 31A-C). Also, using a biotin-DNA pull-down assay (Foulds et al, 2013), we can
demonstrate the in vitro assembly of an ERα/CARM1/MED12 complex on wild-type ERE
(Figure 30C). Finally, we wanted to attempt to determine whether un-methylated MED12 is
recruited to ERE, and subsequently becomes methylated due to the co-recruitment of
CARM1. To do this, we chose to use a reporter/imaging system that allows the quantification
of both ERα and co-regulator recruitment to an ERE array (Bolt et al, 2013). This system
makes use of a HeLa cell line that has an array of EREs (over 100 copies) from the rat
prolactin (PRL) gene integrated into a single genomic locus, and also stably express GFPERα. When these cells are E2-treated you observe the rapid recruitment of GFP-ERα to a
single spot within the nucleus – the PRL array. Immunofluorescence can be used to establish
the recruitment dynamics of co-regulators to this array. We found that MED12 is recruited to
the PRL array (Figure 30D), allowing us to use this approach. We compared the recruitment
dynamics of ERα, total MED12 and methylated MED12. The timing of the recruitment of both
MED12 and methylated MED12 is very similar to that of ERα, suggesting that either MED12
is recruited in the methylated state, or that methylation occurs concomitantly with recruitment.
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Figure 30: E2-dependent recruitment of methylated MED12 to the ER-target gene,
GREB1.
(A) MCF-7 cells were cultured in phenol red-free DMEM supplemented with 10% charcoal
dextran-stripped FBS for 3 days and treated with E2 (50 nM) for 0, 0.5, 1, 4, and 24 hours.
Nuclear extracts were subjected to Western analysis using αmeMED12a, αMED12, αCARM1,
αERα, and αLamin A/C antibodies. (B) MCF-7 cells were cultured in phenol red-free DMEM
supplemented with 10% charcoal dextran-stripped FBS for 3 days and treated with E2 (50
nM) for 0, 0.5, 1, 4, and 24 hours. ChIP experiments were performed with αmeMED12b
antibody. Immunoprecipitated DNA was analyzed by qPCR using primers specific for the
GREB1 gene. Data represent mean of three independent experiments. The y-axis is the fold
change of mean values between peaks and no peak. The x-axis is the hours of E2 treatment.
(C) Schematic showing the wild-type (WT) and mutated (MUT) ERE1 fragment (peak 3) of the
GREB1 gene used for the pull-down experiment. The four nucleotides of the ERE1 fragment
written in bold characters are mutated, which attenuates its binding to ERα. Biotinylated WT
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and MUT fragments were used to pull down endogenous ER-coregulator complexes from the
MCF-7 nuclear extracts. The input and the eluted samples were immunoblotted with
αmeMED12b, αMED12, αCARM1, and αERα antibodies. (D) GFP-ER:HeLa:PRL cells were
treated with 10 nM E2 for the indicated times. The recruitment of methylated MED12, total
MED12, and ER to the PRL array was measured using αmeMED12b, αMED12, and αGFP
antibodies. Image shows overlap between GFP-ER and meMED12b after 1 h of E2 treatment.
Figure 30B – Experiment performed and figure organized by Dr. Donghang Cheng, UT M.D.
Anderson Cancer Center
Figure 30C – Experiment performed and figure organized by Dr. Charles Foulds from Dr. Bert
O’Malley lab, Baylor College of Medicine
Figure 30D – Experiment performed and figure organized by Dr. Fabio Stossi from Dr. Michael
Mancini lab, Baylor College of Medicine
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Figure 31: E2-dependent recruitment of methylated MED12 to TFF1, IGFBP4, and
FKBP4 EREs.
(A, B, and C) MCF-7 cells were cultured in phenol red-free DMEM supplemented with 10%
charcoal dextran-stripped FBS for 3 days and treated with E2 (50nM) for 0, 0.5, 1, 4, and 24
hours. ChIP experiments were performed with αmeMED12b antibody. Immunoprecipitated
DNA was analyzed by qPCR using primers specific for TFF1, IGFBP4 and FKBP4 genes.
Data represent mean of three independent experiments. The y-axis is the fold change of mean
values between peaks and no peak. The x-axis is the hours of E2 treatment.
Figure 31 – Experiment performed and figure organized by Dr. Donghang Cheng, UT M.D.
Anderson Cancer Center
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Chapter 5: Discussion
Sections 5.1 – 5.3 serve as the discussion for Chapter 3
5.1 Substrate specificity of PRMTs
It is well established that arginine residues within RGG/RG sequences, termed
Glycine- and Arginine-rich (GAR) motifs, are preferred sites of methylation for most PRMTs.
Some of the examples include GAR1, hnRNPA1, hnRNPU, hnRNPK, fibrillarin and nucleolin
(Thandapani et al, 2013b). Of the nine known PRMT enzymes, PRMT1, 3, 5, 6, and 8
methylate arginines within GAR motifs, however, not exclusively, as they also have non-GAR
substrates. These non-GAR substrates (E.g. PGCα, ER, FOXO, histones H3, and H4) are
perhaps recognized by PRMTs based on their tertiary structure (Di Lorenzo & Bedford, 2011;
Le Romancer et al, 2008; Teyssier et al, 2005; Yamagata et al, 2008). CARM1 is a unique
enzyme, as it does not methylate GAR containing proteins, it rather methylates PGM (proline, glycine- and methionine-rich) motifs, which are mainly found in splicing factors (Bedford et
al, 1998). It also methylates other substrates that have no obvious common recognition motif.
(Cheng et al, 2007). Many CARM1 substrates (PABP1, SmB’, CA150, U1C, and SF3B4) are
also symmetrically dimethylated by PRMT5 (Cheng et al, 2007). Similarly, many GAR and
non-GAR substrates can also be common targets for Type I and Type II enzymes. For
example, the GAR substrate, nucleolin, is methylated by PRMT1 and PRMT5 (Bedford &
Richard, 2005; Teng et al, 2007). The non-GAR protein, histone H4 (at R3), is a common
target for both Type I (PRMT1, 6,, and 8) and Type II (PRMT5) enzymes. H4R3me2a is
associated with actively transcribed promoters, whereas the H4R3me2s mark colocalizes with
repressive marks in ChIP analysis (An et al, 2004; Wang et al, 2001; Wang et al, 2008). This
example clearly shows the existence of competition among PRMTs for the same substrates.
But, how commonly this happens, especially in non-histone substrates, is unclear. In addition,
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GAR and PGM motifs containing multiple arginine residues may also undergo dual
modifications (ADMA and/or SDMA), which may attribute them different functions.

5.2 Investigating the MMA mark
PRMT7 is the only known Type III enzyme, which has the ability to exclusively
monomethylate arginine residues within substrates (Zurita-Lopez et al, 2012). The enzyme
purified from insect cells had robust activity and was able to methylate all core histones,
preferentially H2B (at R29, 31 and 33) (Feng et al, 2013). This provided the first evidence that
MMA is not only a precursor of ADMA and SDMA, but also a mark that could perhaps be read
by effector molecules and have potential biological roles. However, the catalytic efficiency
(Kcat/Km) of PRMT7 is around 1000 fold lower than those for other PRMTs (PRMT1, 3, 6) (Feng
et al, 2013). This suggests two possible scenarios. One is that PRMT7 only methylates a
select few substrates. Since PRMTs work in a distributive fashion, the other possibility is that
PRMT7 may act as a priming enzyme by transferring the first methyl group to the substrate,
which will then be taken over by another PRMT for asymmetric or symmetric dimethylation.
This is perhaps the likely scenario because of the following reason. Fibrillarin, myelin basic
protein, and SmD3 are proteins known to be dimethylated by PRMT1 and PRMT5. However,
when these proteins are subjected to in vitro methylation by PRMT7, they undergo monomethylation (Zurita-Lopez et al, 2012). This suggests that PRMT7 may prime the substrates
of PRMT1 or PRMT5 for dimethylation. There could also be a third possibility where PRMT7
is a monomethylator as well as a priming enzyme. One of the ways to understand this issue
is to measure the extent of total mono-methylation in wild-type and PRMT7-null cells. In
addition, we also wanted to search for any possible PRMTs with Type III
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Figure 32: Co-immunoprecipitation of GFP-PRMTs with endogenous PRMT1.
HEK293 cells transiently expressing GFP or GFP-PRMTs (PRMT1-9) fusion proteins were
immunoprecipitated with αGFP or αIgG antibodies and subjected to Western analysis with
αPRMT1 (A) or αGFP (B) antibodies. Solid white dots indicate PRMT1 protein coimmunoprecipitated by GFP-PRMT1 and GFP-PRMT8 (C) Western analysis of the input
samples using αGFP antibody. Experiment for figure 32 was performed by Dr. Surbhi Dhar (a
previous post-doc from Dr. Mark Bedford’s lab, UT M.D. Anderson Cancer Center)
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Figure 33: Hyper-monomethylation of SmB/SmB' upon PRMT5 loss.
Whole cell extracts from HeLa-shControl (C) and HeLa-shPRMT5 (kd1 and kd2) cells were
immunoprecipitated with Y12 antibody. The input samples and the Y12 immunoprecipitates
were subjected to Western analysis with αMMA5 antibody.
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activity in addition to PRMT7. Furthermore, we wanted to study how the dynamics of three
types of arginine methylation change upon the loss of major PRMTs (PRMT1 and PRMT5)?
To address these questions, we generated pan antibodies that recognize monomethylated
arginine residues within substrates and studied the methylation patterns in cell lines knocked
out/down for various PRMTs.

5.3 The dominant ADMA activity of PRMT1 keeps the global MMA and SDMA levels in
check.
The ratios of different arginine methylation types in a variety of cell types were
estimated to be 1500:3:2:1 for Arg:ADMA:MMA:SDMA (Matsuoka, 1972). However, upon the
loss of PRMT1, we found that there were global increases in MMA and SDMA levels (Figure
34). Since PRMT1 constitutes for about 90% of total ADMA activity, the absence of it leaves
a large number of substrates unmethylated, making them available for Type II and III
enzymes. This highlights the extent of competition that exists among different methylation
types. We speculated that PRMT1 may heterodimerize with PRMT7 or another PRMT, which
may act as a priming enzyme for PRMT1 and it monomethylates substrates in the absence of
PRMT1. To test this, we transfected HEK293T cells with GFP-PRMTs (PRMT1-9), performed
a GFP immunoprecipitation followed by Western analysis with PRMT1 antibody. We found
that PRMT1 interacted with itself and PRMT8, an enzyme only expressed in brain (Figure 32)
(Lee et al, 2005a). Hence, we concluded that PRMT1 might not function in concert with a
priming enzyme. Although, we did not observe major MMA changes in cell lines depleted for
PRMT3, 4, 5, and 6, there was a specific doublet of bands that migrated at 25kDa in PRMT5
KD cells that was absent in PRMT WT cells (Figure 9D). Based on the size, we speculated
the doublet to be SmB/SmB’, which is a well-studied PRMT5 target (Pesiridis et al, 2009).
Western analysis of SmB/SmB’ proteins immunoprecipitated from wild-type and PRMT5
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knockdown cells confirmed that these proteins are indeed monomethylated upon PRMT5
knockdown (Figure 32). Since PRMT5 knockdown does not completely deplete the cells of
PRMT5, the remaining low levels of enzyme will transfer the first methyl group to the substrate
and release, then the enzyme will likely find another unmethylated substrate (because of its
large pool size), instead of binding with the already monomethylated substrate to convert to
SDMA, thereby hyper-monomethylating the SmB/SmB’ proteins. However, this hypothesis
does not hold true in the case of PRMT1 knockout cells for two reasons. First, PRMT1 is
completely knocked out in these cells. Second, PRMT1 is a partially-processive enzyme
(Obianyo et al, 2008), as opposed to PRMT5, which catalyzes in a distributive fashion
(Antonysamy et al, 2012).
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Figure 34: Dynamic interplay between the three types of arginine methylation.
Upon the loss of PRMT1, there are major increases in global MMA and SDMA levels, whereas
ADMA levels were reduced. This is likely due to the fact that PRMT1 accounts for more than
90% of ADMA activity and the loss of this enzyme could lead to the accumulation of a number
of unmethylated substrates, which then become targets for Type II and Type III enzymes.
Figure 34 is adapted and modified from Yang Y, Bedford MT (2013) Protein arginine
methyltransferases and cancer. Nat Rev Cancer 13: 37-50.
Permission has been acquired from the journal to use this figure.
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Sections 5.4 – 5.6 serve as the discussion for Chapter 4

5.4 CARM1 methylates a distinct motif
Most PRMTs methylate glycine-arginine-rich (GAR) domains (Thandapani et al,
2013a); CARM1 does not. The ill-defined nature of the CARM1 methylation motif can best be
seen when a large number of different CARM1 methylation sites are aligned (Figure 35).
There is clearly no obvious motif, except for the propensity for proline residues in the vicinity
of the CARM1 methylation site. But even the proline residues are not at a fixed position from
the methylated arginine, suggesting that all that is needed is a kink, on either side (or both
sides) of the methylation site. Thus, even after the identification of a number of different
CARM1 substrates, the methylation motif for this enzyme still remains rather nebulous. Cocrystal structures of CARM1 with H3 and PABP1 peptides were resolved. While substrate
arginine makes hydrogen bond interactions with certain key residues in CARM1, residues
surrounding the arginine interact through their backbone atoms, suggesting that substrate
recognition by CARM1 is largely sequence-independent. However, since the CARM1
crystallization construct used in this study is truncated, it is possible that the missing domains
may make additional interactions with the peptide that are necessary for substrate recognition.
In addition, the length of the substrate peptides used may also play a role. In fact, long-range
interactions between PRMT1 and histone H4 were shown to be critical for substrate binding
and catalysis (Osborne et al, 2007). Interestingly, although it is difficult to predict a CARM1
substrate, antibodies developed to one substrate often cross-react with other substrates – so
antibodies are able to identify some structural similarity between CARM1 methylation motifs.
This “semi-pan” nature of CARM1 substrate antibodies was first realized using the
H3R17me2a antibody, which we have shown recognizes
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CARM1 Substrate
BAF155 (R1064)
CAS3 (R88)
CBP (R714)
CBP (R742)
CBP (R768)
CTD (R1810)
GPS2 (R312)*
GPS2 (R323)*
H3 (R17)
H3 (R26)
HuD (R236)
HuR (R217)
MED12 (R1899)*
MLL2 (R3727)*
p300 (R2142)
p300 (580)
PABP1 (R455)
PABP1 (R460)
Pax7 (R10)
Pax7 (R13)
Pax7 (R22)
Pax7 (R37)
Sox2 (R113)
Sox9 (R152)
Sox9 (R74)
SRC3 (R1171)
TARPP (R650)

Methylated motif
PPMPGNILGPRVPLTAPNGMY
NPYQTAVYPVRSAYPQQSPYA
PNGPLSLPVNRMQVSQGMNSF
VQLPQAPMGPRAASPMNHSVQ
SVPGMAISPSRMPQPPNMMGA
TSPSYSPSSPRYTPQSPTYTP
GFAATSQPGPRLPFIQHSQNP
LPFIQHSQNPRFYHKXXXXXX
ARKSTGGKAPRKQLATKAARK
PRKQLATKAARKSAPATGGVK
YPGPLHHQAQRFRLDNLLNMA
FGGPVHHQAQRFRFSPMGVDH
EPSSYKTSVYRQQQPAVPQGQ
QERQLQLQQQRMQLAQKLQQQ
NMNPMQAGVQRAGLPQQQPQQ
QWHEDITQDLRNHLVHKLVQA
HPFQNMPGAIRPAAPRPPFST
MPGAIRPAAPRPPFSTMRPAS
XMAALPGTVPRMMRPAPGQNY
ALPGTVPRMMRPAPGQNYPRT
MRPAPGQNYPRTGFPLEVSTP
LEVSTPLGQGRVNQLGGVFIN
KEHPDYKYRPRRKTKTLMKKD
LWRLLNESEKRPFVEEAERLR
SEEDKFPVCIREAVSQVLKGY
RPRTNTPKQLRMQLQQRLQGQ
QYPTSTSQQYRPLASVQYSAQ

Reference
(Wang et al, 2014a)
(Lee & Bedford, 2002)
(Chevillard-Briet et al, 2002)
(Chevillard-Briet et al, 2002)
(Chevillard-Briet et al, 2002)
(Sims et al, 2011)
(Huang et al, 2015a)
(Huang et al, 2015a; Jarmalavicius et al, 2010)
(Bauer et al, 2002; Chen et al, 1999)
(Chen et al, 1999; Schurter et al, 2001)
(Fujiwara et al, 2006)
(Li et al, 2002)

(Lee et al, 2005b)
(Xu et al, 2001)
(Lee & Bedford, 2002)
(Lee & Bedford, 2002)
(Kawabe et al, 2012)
(Kawabe et al, 2012)
(Kawabe et al, 2012)
(Kawabe et al, 2012)
(Zhao et al, 2011)
(Ito et al, 2009)
(Ito et al, 2009)
(Feng et al, 2006)
(Kim et al, 2004)

Figure 35: Alignment of CARM1-methylated motifs.
A selection of CARM1-methylated motifs containing 20 amino acids surrounding the central
arginine residue was aligned using the MegAlign software (DNASTAR, Inc). The central
arginine and the neighboring prolines were highlighted in black and grey, respectively.
Asterisk indicates methylation sites identified in this study.
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SRC3 (Naeem et al, 2007) and CA150 (Cheng et al, 2007), and here we show also recognizes
GPS2, SLM2, PABP1, SF3B4, SRC1 and MED12 (Figure 17B).
The use of methyl-specific antibodies combined with MS-based proteomic analysis
has led to the discovery of a number of arginine-methylated proteins (Boisvert et al, 2003;
Guo et al, 2014; Ong et al, 2004b). However, these methyl-specific antibodies were raised
against GAR-motifs, making them unsuitable for use in enriching CARM1 substrates. To
address this issue, we developed antibodies against a mixture of CARM1-methylated motifs
and identified over a 100 putative CARM1 substrates by IP-MS (Figures 15 & 17). The
enrichment of known CARM1 substrates like SRC3, CA150, and SF3B4, whose methyl-motifs
were not used in antibody generation, validates our strategy. The antibodies also enriched for
a few known PRMT1 substrates including Sam68 (Cote et al, 2003), G3BP1 (Bikkavilli &
Malbon, 2011) and DHX9 (Smith et al, 2004). Secondary screening was performed on a small
subset of the identified proteins, using CARM1 knockdown and knockout cells (Figure 18),
and we validated three novel CARM1 substrates – GPS2, KMT2D, and MED12. Interestingly,
SLM2 methylation is not lost upon CARM1 knockdown (Figure 18I), although this protein is
recognized by a number of CARM1 substrate motif antibodies.
All four of these newly confirmed CARM1 substrates have biological activity on or near
chromatin. Indeed, GPS2 is a dual-function protein that acts both as a corepressor and
coactivator for various transcription factors (Wong et al, 2014a). It has been reported that
GPS2 is methylated at R323 (one of the two methyl sites identified in our MS data). Recently,
it was found that the H3R17me2a antibody recognizes GPS2 (Huang et al, 2015b), and that
PRMT6 can methylate GPS2 in vitro, but CARM1 was never tested in this assay. In addition,
the site of PRMT6 methylation on GPS2 was mapped to R323 and this methylation seems to
be required for GPS2 protein stabilization. Thus, there may be two independent sites of
methylation on GPS2 (R312 & R323), and both CARM1 and PRMT6 may compete for this
substrate. KMT2D is a lysine methyltransferase, primarily responsible for mono-methylating
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H3K4 at active enhancers (Guo et al, 2013; Hu et al, 2013; Lee et al, 2013). We report that
KMT2D is arginine methylated at R3727 residue. The functional role of this methylation event
is unclear, but it is interesting that KMT2D and CARM1 both have activity at enhancers, and
may be “talking” to each other. The RNA-binding protein SLM2 was reported to be arginine
methylated by PRMT1 (Cote et al, 2003). Here, we show that SLM2 is also recognized by
CARM1 substrate antibodies, suggesting that PRMT1 may not be the sole methyltransferase
for this protein. Finally, MED12 was previously identified as an arginine methylated protein in
two independent studies. Using hydrophilic interaction liquid chromatography (an antibodyindependent approach) to enrich for tryptic peptides that contain methylated arginine residues,
the Acuto group identified the same site that we did (R1899) as a prominent site of arginine
methylation, although they did not determine the enzyme responsible for the methylation
(Uhlmann et al, 2012). Subsequently, Xu group identified MED12 in a screen that used ADMA
antibody raised to a redundant XXRme2aXX motif (Guo et al, 2014), to enrich for proteins that
were methylated in CARM1 WT but not CARM1 KO breast cancer cell lines (Wang et al,
2014a). Using in vitro binding assays, they were able to show that GST-CARM1 interacted
with full-length MED12. However, we did not observe a co-immunoprecipitation between
endogenous CARM1 and MED12 (Figure 21A). It is possible that the transient interaction
needed to achieve methylation is what is detected in the in vitro binding assay. Using deletion
analysis, they showed that MED12 is methylated at R1862, which is distinct from the site
identified in the current study (R1899). Methylation at this site was shown to sensitize breast
cancer cells to chemotherapy drugs by enhancing Mediator recruitment to p21 gene locus and
suppressing its transcription. Consistent with these reported findings, using the more focused
ADMACARM1 antibodies, we also identified MED12 as a methylated protein. We showed that
MED12 is methylated by CARM1 and is recruited to the ER∝-specific enhancers. We propose
that methylated MED12 functions in maximizing ER∝-mediated transcription, possibly by
recruiting the coactivator, TDRD3.

102

5.5 CARM1 primarily associates with enhancers, but is also found at promoters
By exploiting the pan nature of the H3R17me2a antibody, CARM1 activity was first
mapped in a global fashion by the group of Myles Brown, using a ChIP-on-chip approach
(Lupien et al, 2009). They found that the majority (70%) of ERα binding sites are associated
with CARM1 activity. Most of the CARM1 activity mapped to intergenic and intronic regions,
with less than 3% of this activity associated with proximal promoter regions. Our expanded
H3R17me2a ChIP-seq data support these findings.
The association of CARM1 itself with chromatin has been investigated using a reChIPon-chip approach (Coughlan et al, 2013). In this study from Joe Torchia’s group, a promoter
array was used for the profiling, so they were not able to investigate enhancer enrichment of
CARM1. However, the SRC3/CARM1 protein complex associated not only with promoter
proximal EREs, but also with Sp1 and C/EBP1 binding motifs. Importantly, the Sp1 motif is
enriched in the YYN and YNN clusters that are associated with CARM1 activity at promoters
that are also marked with H3K4me3 signal (Figures 25B & 26B). The reChIP-on-chip
experiment focused on identifying promoters that recruited CARM1 through its association
with SRC3 (Coughlan et al, 2013). This is likely just a subset of promoters that are engaged
by CARM1, because it can be recruited by other SRCs and also directly by other transcription
factors themselves. Indeed, CARM1 interacts directly with ERα, and in an estrogenindependent manner

in response to cAMP signaling (Carascossa et al, 2010), and also with

c-Fos (Fauquier et al, 2008) and C/EBPβ (Kowenz-Leutz et al, 2010). CARM1 not only binds,
but also methylates C/EBPβ and inhibits the association of this transcription factor with the
Mediator complex (Kowenz-Leutz et al, 2010). NF-κB is another transcription factor that
directly interacts with CARM1 (Covic et al, 2005), and it was later reported that CARM1 is
present at the promoter/enhancer looping joint of a NF-κB regulated gene (MCP-1)
(Teferedegne et al, 2006). In this setting, CARM1 was not required for looping, but was
required for efficient expression of MCP-1. CARM1 also binds directly to the Notch intracellular
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domain (NICD), and can be detected at NICD-bound enhancer sites of a number of Notch
target genes (Hein et al, 2015). Thus, CARM1 is not a dedicated ER coactivator, but is also
recruited by other transcription factors to both proximal promoters and enhancer elements.
CARM1 is not only recruited to chromatin by transcription factors, but also by ATPdependent remodeling complexes, including the SWI/SNF complex (Xu et al, 2004) and direct
interactions with Mi2α and Mi2β, components of the NuRD complex (Streubel et al, 2013).
Although NuRD is generally considered a transcriptional repressor complex, there is emerging
evidence that it can also positively regulate gene expression, particularly in light of recent
genomic localization studies that show its enrichment at active promoters and enhancers
(Shimbo et al, 2013).
At both enhancer elements and at some proximal promoters, CARM1 methylates a
host of different proteins that are detected with the H3R17me2a antibody. However, it is clear
that the H3R17me2a antibody does not recognize all CARM1 substrates (Figure 17B –
KMT2D & SRC2). This is supported by our ChIP-seq data showing two categories (YYN &
YNN) that display strong CARM1 recruitment but very little H3R17me2a antibody ChIP signals
(Figure 25B). It is likely that CARM1 activity at these proximal promoter regions will be
detected using a different CARM1 substrate antibody. These data support the idea of distinct
methylarginine “fingerprints” on transcriptional coactivators, at different gene promoters and
enhancers, which was first proposed by the Gronemeyer group (Ceschin et al, 2011). In that
study, they showed that three methyl-specific antibodies, raised against different CARM1
methylation sites on the CREB-binding protein (CBP), displayed dissimilar localization
signatures at different EREs.
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5.6 How does CARM1 methylation of MED12 regulate its function?
CARM1 impacts gene expression pathways at multiple stages; it methylates the
SWI/SNF chromatin remodeling protein, BAF155, to modulate chromatin structure at c-Mycregulated genes. It affects transcription initiation by methylating histone H3, SRCs, and
p300/CBP. It also regulates mRNA splicing by methylating CA150 and other splicing factors.
Furthermore, CARM1 modifies PABP1, HuR, and HuD to regulate post-splicing events, such
as mRNA stability. We demonstrate here that methylation of MED12 provides an additional
level of gene expression regulation governed by CARM1. While the Mediator complex broadly
regulates transcription, the MED12 subunit is only partially methylated in cells (Figure 19D),
suggesting that the Mediator complex targeted by CARM1 may regulate a specific set of
transcriptional programs, as opposed to all RNAPII-dependent genes. From ChIP-seq
experiments, we defined this specific set of genes to be ERα-dependent. We are currently
performing gene expression studies to determine if MED12 methylation enhances the
activation of these genes.
Methylation of MED12 signals the recruitment of TDRD3, which may promote
transcriptional activation because of TDRD3’s coactivator activity (Yang et al, 2010). TDRD3
is in a tightly complex with the topoisomerase, TOP3B (Stoll et al, 2013; Yang et al, 2014). It
has been shown that the TDRD3/TOP3B complex is recruited to active chromatin through the
ability of the TDRD3 Tudor domain to interact with the H3R17me2a and H4R3me2a marks
(Yang et al, 2014). Here we report a third mark that is “read” by TDRD3: MED12R1899me2a.
The recruitment of the TDRD3/TOP3B complex could help resolve R-loops at sites of active
transcription (Yang et al, 2014), or it could act on ncRNA molecules that are associated with
the Mediator complex. Indeed, TOP3B was recently shown to possess both DNA and RNA
topoisomerase activities (Xu et al, 2013; Yang et al, 2014). Importantly, Mediator has been
shown to associate with at least two classes of non-coding RNAs; 1) activator RNAs (aRNAs,
also called ncRNA-a) that increase the transcription of neighboring genes (Lai et al, 2013),
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and 2) enhancer RNAs (eRNAs) that correlate with enhancer-promoter looping and gene
activation (Hsieh et al, 2014). The recruitment of the TDRD3/TOP3B complex, and its dual
topoisomerase activity, may be required for not only reducing R-loop formation in the wake of
Pol II at active genes (though a H3R17me2a and H4R3me2a interactions), but also for the
“untangling” and “correct” structural presentation of these RNA scaffolds at sites of enhancerpromoter looping (though a MED12R1899me2a interaction) (Figure 30E).

106

Chapter 6: Future studies

Currently, I am performing gene expression studies to determine if MED12 methylation
regulates transcription of ER-target genes. This requires the generation of ER positive breast
cancer cell lines depleted of endogenous MED12 and rescued with MED12 wildtype and
R1899K constructs. Owing to its large size, overexpression of MED12 plasmid using chemical
transfection methods proved difficult to achieve. In addition, RNAi-mediated knockdown of
endogenous MED12 was only partially successful. To circumvent these issues, we planned
to use lentiviral-mediated transduction method and generate five MCF-7 cell lines that express
(i) Scramble shRNA and FLAG-empty (ii) MED12 shRNA and FLAG-empty (iii) MED12 shRNA
and shRNA-resistant MED12 wild-type (iv) MED12 shRNA and shRNA-resistant MED12
R1899K and (v) MED12 shRNA and shRNA-resistant MED12 R1862K vectors. These cells
will be treated with Estrogen (50 nM, 1 h), validated by Western analysis and tested for gene
expression changes by RT-qPCR. We hypothesized that MED12 R1899 methylation
enhances ER-mediated transcription and hence, we expect to see reduced ER-target gene
expression in mutant (R1899K) cells (iv) compared to their wild-type counterparts (iii). The cell
line (v) will determine if the R1862 methylation, identified by the Xu group, is also important in
mediating ER signaling (Wang et al, 2015). We do not expect that MED12 methylation will
negatively regulate these target genes, for two reasons: CARM1 is a coactivator for nuclear
hormone receptors (Chen et al, 1999) and MED12 knockdown reduces the expression of ER
target genes and ESR1 gene itself (Prenzel et al, 2012). It is also possible that MED12
methylation may function redundantly in recruiting TDRD3 to NR target gene loci and hence,
may not produce a significant effect on transcription. In this unlikely, yet possible scenario, we
will focus our efforts of
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Figure 36: MED12 associates with activating ncRNAs in a CARM1-dependent manner.
MCF-7-Tet-on-shCARM1 cells were untreated or treated with doxycycline (1 μg/ml) for 8 days.
The cells were ultraviolet crosslinked at 254 nm (200 mJ/cm2) in 10 ml ice-cold PBS, lysed in
mild buffer and immunoprecipitated with αMED12 antibody. Total RNA is then extracted from
the immunoprecipitates, converted to cDNA and analyzed by RT-qPCR using primer sets
specific for ncRNA-a1, -a3 and -a7 genes.
Figure 36 – RIP experiment performed and figure organized by Dr. Donghang Cheng. I did
validation of CARM1 KO and MED12 IP-WBs.
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Figure 37: Mutant MED12 shows reduced interaction with activating ncRNAs.
HEK293T cells were transiently transfected with FLAG-MED12-WT or FLAG-MED12-MUT
constructs. The cells were ultraviolet crosslinked at 254 nm (200 mJ/cm2) in 10 ml ice-cold
PBS, lysed in mild buffer and immunoprecipitated with αFLAG antibody. Total RNA is then
extracted from the immunoprecipitates, converted to cDNA and analyzed by RT-qPCR using
primer sets specific for ncRNA-a1, -a3 and -a7 genes.
Figure 37 – RIP experiment performed and figure organized by Dr. Donghang Cheng. I did
validation of MED12 WT and MUT protein expression.
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Figure 38: MED12 associates with activating ncRNAs in a TDRD3-dependent manner.
MCF-7-Tet-on-shTDRD3 cells were untreated or treated with doxycycline (1 μg/ml) for 8 days.
The cells were ultraviolet crosslinked at 254 nm (200 mJ/cm2) in 10 ml ice-cold PBS, lysed in
mild buffer and immunoprecipitated with αMED12 antibody. Total RNA is then extracted from
the immunoprecipitates, converted to cDNA and analyzed by RT-qPCR using primer sets
specific for ncRNA-a1, -a3 and -a7 genes.
Figure 38 – RIP experiment performed and figure organized by Dr. Donghang Cheng. I did
validation of TDRD3 KO and MED12 IP-WBs.
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understanding the biological roles of MED12 methylation in the activating ncRNA (ncRNA-a)
field. MED12 was shown to associate with activating ncRNA (a1, a3, and a7) (Lai et al, 2013).
We performed RNA immunoprecipitation (RIP) experiments and found that MED12 associates
with these ncRNAs in a CARM1-dependent manner in MCF-7 cells (Figure 36). We also
overexpressed FLAG-MED12 wild-type and mutant (R1899K) in HEK293T cells and found
that the methyl-mutant showed reduced association with the three ncRNAs when compared
with the wild-type protein (Figure 37). In addition, we showed that methyl-MED12 antibody
was able to pull down these ncRNAs in MCF-7 cells (data not shown). Furthermore, we
showed that MED12 interaction with ncRNA-a7 is also dependent on TDRD3 (Figure 38).
These findings led us to hypothesize that methyl-MED12-associated TDRD3 may act as an
interface that links ncRNA-a with their target gene loci to promote their transcription. As a
secondary confirmation, we will perform RIP-seq experiments using RNA isolated from
MED12 immunoprecipitates of wild-type and CARM1- and TDRD3-knockdown cells. To test
our hypothesis, the cell lines (i-iv) will be infected with a lentivirus expressing TK promoterdriven luciferase reporter, which is fused to the ncRNA (a1, a3 or a7) gene driven by its natural
promoter. The effect of MED12 methylation on ncRNA target gene activation can be measured
by the changes in luciferase activity. In addition, the expression of ncRNA-a target genes
(TAL1, STIL, SNAI1, UBE2V1, AURKA, and CSTF1) in cell lines (i-iv) will be also tested.
These target genes were shown to be activated by CDK8-mediated phosphorylation of
H3S10, a histone mark linked with transcriptional activation (Lai et al, 2013; Nowak & Corces,
2004). We noted earlier that MED12 methylation does not have an effect on Mediatorassociated kinase activity (Figure 22) at the global level. However, there may be a MED12
methylation-dependent CDK8 regulation at the gene specific level. Phospho-H3S10 chIP at
these target gene loci in wild-type and methyl mutant cell lines will be performed. If the above
studies hold true, chromosome conformation capture (3C) should be performed to confirm the
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association of ncRNAs with their target gene promoters in MED12 wild-type versus methylmutant cell lines.
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Chapter 7: Significance

In order to better understand PRMT functions in normal physiology as well as to
develop therapeutic targets, many PRMT inhibitors have been identified and some of them
have proven effective in ameliorating symptoms in animal disease models (Alinari et al, 2015;
Chan-Penebre et al, 2015; Panfil et al, 2015; Sun et al, 2012). Bedford group identified the
first class of small molecule inhibitors (AMI series) that specifically targeted PRMTs, but not
other AdoMet-dependent methyltransferases (Cheng et al, 2004). AMI-1, which targets
PRMT1, 3, 4, and 6, was shown to alleviate asthmatic symptoms in AIP1 (Ag-induced
pulmonary inflammation) rat model (Sun et al, 2012). Later on, more selective inhibitors were
identified. A PRMT5 inhibitor has been reported to have anti-tumor effects in Mantle cell
lymphoma (MCL) xenograft model (Chan-Penebre et al, 2015). While the knowledge of PRMT
crystal structures aided in identifying small molecule inhibitors, validating them requires
additional tools. Methyl-specific antibodies are proving valuable in assessing the efficacy and
selectivity of these PRMT small molecule inhibitors. For example, a pan-SDMA antibody was
used to measure the loss of PRMT5 activity in PRMT5 inhibitor-treated MCL cell lines (ChanPenebre et al, 2015). A selective CARM1 inhibitor was also identified that inhibited methylation
of CA150, PABP1, and SmB strongly, however H3 weakly, as detected by the antibodies
specific for individual substrates (Cheng et al, 2011). Hence, there is a need for developing
better CARM1 inhibitors and CARM1 substrate motif antibodies generated in this study will
act as great tools for characterizing their selectivity. Similarly, MMA antibodies generated in
the first study can be used to validate loss of PRMT1 activity, which is measured by the
increase in monomethylation signal. Recently, we have tested a new set of PRMT inhibitors
in our lab. As anticipated, PRMT1 inhibitor treated cells showed an increase in MMA signal
and a decrease in ADMA signal (top and middle panels – Figure 39). However, the CARM1
inhibitor did not prove effective in eliminating or
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Figure 39: Testing the efficacy of PRMT inhibitors using methyl-specific antibodies.
HeLa cells were treated with DMSO, PRMT1 (1 μM), PRMT4/CARM1 (2 μM) or PRMT5 (5μM)
inhibitors for 4 days. Whole cell extracts were subjected to Western analysis using the
specified antibodies.
Figure 39 – Experiment performed and figure organized by Dr. Guozhen Guo
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reducing the signal on CARM1 substrates, as detected by H3R17me2a antibody (middle
panel – Figure 39). PRMT5 inhibitor showed a dramatic decrease in SDMA signal (bottom
panel – Figure 39), proving its efficacy. The same held true for MLL-ENL leukemic cell lines
treated with the three PRMT inhibitors (Collaboration with Santos group). In addition, antiproliferative effects were observed in PRMT5 inhibitor-treated MLL-ENL cell lines (data not
shown).
In addition to small molecule inhibitor validation, MMA antibodies can be used to
identify novel PRMT1 and PRMT7 substrates. Wild-type, PRMT1 knockout, and PRMT7
knockout MEF extracts can be immunoprecipitated with MMA antibodies and the eluates can
be subjected to mass spectrometry to identify differentially recognized proteins.
In the second study involving CARM1 substrate motif antibodies, we have only tested
a small subset of the 112 MS-identified potential CARM1 substrates. IP-WB experiments may
uncover more unknown substrates, in addition to GPS2, MLL2, and MED12. Unlike p300/CBP
and the NCoA family, if methylated MED12 proves to be a dedicated coregulator of ERα
signaling, an inhibitor targeting methylated MED12, but not unmodified MED12, may
specifically impact ER pathway and possibly hold some therapeutic value. MLL2 (or KMT2D),
another substrate identified in this study, is recurrently mutated in multiple cancers. Studying
the biological role of MLL2 methylation may clarify its possible tumorigenic functions. It is
notable that R3727 and R4198 sites, methylated by CARM1, were mutated in melanoma, lung
and pancreatic cancers (TCGA database).
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